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                                                         ABSTRACT 
TITLE OF THE ABSTRACT: Antibodies to acetylcholine receptor antibody titre, anti 
desmoglein antibody titre and disease activity in pemphigus patients. 
DEPARTMENT: Department of Dermatology , Venereology and Leprosy. 
NAME OF THE CANDIDATE: L.Rosemary 
DEGREE AND SUBJECT: M.D. Dermatology, Venereology and Leprosy 
NAME OF THE GUIDE: Dr. Dincy Peter 
OBJECTIVES: Correlation of acetylcholine receptor antibody titre with disease activity 
measured by PDAI and desmoglein antibody titre in pemphigus patients  
METHODS: In this study, 77 Pemphigus vulgaris patients both naïve and on treatment 
were recruited after obtaining their consent. Data on demographic profile, duration of 
illness, subtype of pemphigus vulgaris, treatment details were recorded. At the time of 
initial presentation the disease severity was evaluated by pemphigus disease area index 
score. Anti desmoglein antibody titre and acetycholine receptor antibody titre was 
estumates using ELISA kit and then compared with PDAI score. Pearsons product 
moment correlation coefficient was used to correlate PDAI score with AChRAb titre and 
anti desmoglein antibody titre. 
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RESULTS: The mean age of the patient was 46yrs and there was female preponderance 
with a male:female ratio of 1:1.2 . Mucocutaneous subtype (75%) of pemphigus was 
predominant in the study group with majority (40%) of them with raised titres of both 
Dsg1 and Dsg3. In mucosal type of pemphigus, 10% of them had raised titres of anti 
Dsg3 antibody but Dsg1 antibody positivity was not seen. Majority (55%) of them had 
mild disease. About 17 patients (22%) of study population had positive titres of AChRAb 
titre. There was significant statistical correlation of PDAI score with anti Dsg1 and Dsg3 
antibody titre.(p-value - <0.01). There was no statistical significant correlation of 
AChRAb titre with PDAI score and anti desmoglein antibody titre. 
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INTRODUCTION 
Pemphigus is a life threatening autoimmune intraepidermal bullous disorder(1). It is 
characterised by formation of flaccid blisters on skin and mucous membrane. The 
worldwide incidence of pemphigus is about 0.1-0.5 patients per 1,00,000 population per 
year(2). Pemphigus vulgaris is the commonest type of autoimmune bullous disorder seen 
worldwide(1). It is also the predominant type of autoimmune bullous disorder seen in 
India(3–6). The pathomechanism underlying pemphigus vulgaris is the process called 
acantholysis resulting in separation of keratinocytes from each other. It is due to 
autoantibodies directed against adhesion molecules like desmoglein antigens and various 
other nondesmoglein antigens present on the surface of keratinocytes leading to the 
formation of bulla in the epidermis. Other nondesmoglein antigens involved in the 
pathogenesis of pemphigus includes cholinergic receptors, desmocollins and 
plakoglobulins. Cholinergic receptors are the newer immunologic targets described in the 
pathogenesis of pemphigus(6). There are different types of cholinergic receptors present 
on the surface of keratinocytes. Endogenously secreted acetylcholine activates these 
cholinergic receptors and helps to maintain the shape and adhesion of keratinocytes. 
These cholinergic receptors were found at the site where acantholysis occurs, thereby 
proving their role in regulation of adhesion of keratinocytes(7). The pathogenesis of 
pemphigus is unclear and still under intense research. 
 The disease severity varies from mild to life threatening disease and thus it is necessary 
to categorise the disease. There are various scoring system proposed to assess the severity 
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of disease. Of these, pemphigus disease area index (PDAI) is highly a validated, reliable, 
reproducible scoring system with higher intra-rater reliability in comparison to 
autoimmune bullous skin disorder intensity score(ABSIS)(8). It measures the disease 
severity over trunk, extremities, scalp and mucosa.  
The desmoglein antibody titres were found to correlate with disease severity in 
pemphigus vulgaris(9). Daneshpazhooh et al. in his study demonstrated that Dsg ELISA 
is a useful tool to assess disease severity and to monitor disease activity. He also proved 
the correlation of clinical phenotype of pemphigus patients with desmoglein antibody 
profile. He found that anti Dsg1 titre correlated with severity of cutaneous involvement 
and anti Dsg3 titre correlated with severity of oral mucosal involvement. But in 
occasional cases he noticed discordance between clinical phenotype and desmoglein 
antibody profile. This discrepancy was postulated to be due to genetic variation or 
presence of minor antigens which is involved in the pathogenesis of pemphigus(10).  
These minor antigens includes nondesmoglein antigens like cholinergic receptors. 
Sanchez et al. correlated the acetylcholine M3 receptor antibody titre with disease 
severity measured by body surface area (BSA) and compared with Dsg3 antibody titre. 
He observed that there is mild rise in acetylcholine receptor antibody titre and it 
correlated well with disease severity and Dsg3 antibody titre at the initial presentation 
and also during follow up(11). The mainstay of treatment for pemphigus includes 
corticosteroids which has reduced the mortality from 90%to 10%. Grando and Dahl 
observed that antiacantholytic effect of cholinomimetics on keratinocytes in vitro(12). 
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This discovery unraveled a search for nonhormonal drug in the treatment of pemphigus to 
ameliorate side effects of steroid.  
There are not many studies looking at acetylcholine receptor antibody titre and its 
correlation with disease activity of pemphigus and there are no published Indian studies. 
Hence, we proposed to conduct a study in pemphigus patients to correlate the disease 
activity as measured by PDAI scoring with cholinergic receptor antibody titre and with 
anti Dsg1 and anti Dsg3 antibody titre. 
 
 
 
 
 
 
                     
 
                                                          
AIMS AND OBJECTIVES 
Aim:  
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To determine the correlation of disease activity with titres of antibodies   against  
acetylcholine muscarinic (M3) receptors in patients with pemphigus. 
Objectives: 
 Primary objective:  
1) To estimate the prevalence of acetylcholine receptor antibodies in patients with 
pemphigus. 
2) To correlate the serum anti acetylcholine receptor antibody titres with clinical disease 
activity as measured by the pemphigus disease area index (PDAI) in patients with 
pemphigus. 
Secondary objective:  
To compare the values of the serum anti acetylcholine receptor antibody titres with anti 
desmoglein antibody titres in patients with pemphigus. 
 
 
 
 
                                              REVIEW OF LITERATURE 
Introduction: 
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Pemphigus vulgaris is an autoimmune epidermal bullous disease that results in blistering 
of the skin and mucosal surfaces(13).The word pemphigus is derived from the Greek 
word, pemphix meaning blister or bubble(2). In pemphigus patients there is production of 
autoantibodies which are directed against desmoglein antigens on the surface of 
keratinocytes. This leads to loss of their cellular attachment and separation from one 
another forming blisters within the epidermis(13). Pemphigus has varied clinical 
manifestations which is based on the variation in the distribution of implicated antigens 
in different layers of epidermis and in different regions of the body(2). The diagnosis of 
pemphigus is based on the clinical manifestations (flaccid blisters and erosions on skin 
and oral mucosa), histopathology (epidermal acantholysis), and direct 
immunofluorescence (demonstrates IgG and C3 deposition in the intercellular region of 
epidermis in a fish net pattern)(2). The pathogenic circulating antibodies in pemphigus 
patients are of IgG type and is directed against desmosomal cadherins desmoglein 1 and 
desmoglein3. These desmoglein antibody titres are measured by ELISA method which is 
a specific and sensitive test to diagnose pemphigus vulgaris. According to Dr.Grando and 
Nguyen, apart from desmoglein antibodies, there may be other additional antibodies 
against cholinergic receptors which are involved in the pathogenesis of pemphigus 
vulgaris(14). Grando proposed a list of autoantigens involved in the pathogenesis of 
pemphigus. These autoantigens include desmocollins, plakoglobulin, BP180 and 
cholinergic receptor molecules like α3 AChR, α9 AChR, pemphaxin and other annexins, 
FcєRIα(12). The significance of antibodies against different cholinergic receptors 
involved in the pathogenesis of pemphigus is yet to be proven. 
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Epidemiology:  
Pemphigus vulgaris is a disease of the middle age group and affects all races and both 
sexes. It rarely affects children. Pemphigus vulgaris accounts for around 70% of all cases 
of pemphigus occurring worldwide and may be the commonest autoimmune blistering 
disease in Eastern countries, such as India, Malaysia, China and the Middle  East(15). 
There is increased susceptibility of the Jewish race, especially Ashkenazi Jews to 
pemphigus vulgaris and has a link to HLA class II alleles(16). Pemphigus vulgaris is 
commoner in Indians of South Africa, than in Black or Caucasian races. It is less 
common in the West(15).  
Epidemiology,  Indian scenario: 
Epidemiology of pemphigus in India has shown a different trend in comparison to 
Western literature(17). One Indian study have shown an early onset of disease i.e. onset 
below 40 years of age in majority of pemphigus patients(18). This in contrast to the 
studies from other parts of the world where the age of onset has been recorded as between 
40yrs and 60yrs. Among the dermatology outpatient attendees, the incidence of 
pemphigus was found to vary between  0.09% to 1.8%(3)(18). In Thrissur district of 
Kerala, southern India the incidence of pemphigus was assessed based on a questionnaire 
survey and was found to be 4.4 million per population per year.  
 
Aetiology:  
Pemphigus is a genetically predisposed disease. Certain class II major histocompatibility 
complex (MHC) antigens have a markedly increased frequency in pemphigus vulgaris 
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patients. HLA class II alleles DRB1*0402, DRB1*1401 and DQB1*0302 are seen in 
Caucasians and DRB1*14 and DQB1*0503 in Japanese. MHC class II alleles encodes 
cell surface molecules and they are necessary for antigen presentation to immune system. 
Therefore it is hypothesized that these alleles helps in the presentation of the desmoglein 
3 peptide to T cells. Certain peptides of desmoglein 3 is predicted to fit into DRB1*0402 
peptide binding pocket on T cells and stimulates T cells thereby proving the hypothesis. 
Pemphigus autoantibodies against desmoglein antigens are of IgG isotype. First degree 
relatives of pemphigus patients have higher incidence of circulating anti- desmoglein 
antibodies. Pemphigus patients are at greater risk of developing certain diseases with 
immunological disturbances like Thymoma and Myasthenia gravis. Certain triggering 
factors of the disease includes pesticides, drugs, infections, certain foods containing 
tannins, phenols and thiols, hormones (disease exacerbation during pregnancy) ultraviolet 
radiation and stress(19). 
Pathogenesis: 
All patients of pemphigus vulgaris have circulating and skin-fixed autoantibodies 
directed against keratinocyte cell-surface antigens called desmosomes(2). In most cases 
the triggering factor of intercellular autoantibodies against desmosomes is unknown. But 
in some individuals it is known to be triggered by drugs(13). The most important 
predisposing factor is HLA association(2). It was in 1964 that Beutner and Jordan made 
the discovery of circulating IgG antibodies against keratinocyte surface antigens(20). 
And in 1980 the pathogenicity of these antibodies was proved. These antibodies when 
passively administered to neonatal mice induced acantholysis(21)(22). They have also 
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been found to be capable of inducing acantholysis in organ cultures of human skin(23). 
The placental transfer of these autoantibodies to the newborn babies born from mothers 
of active pemphigus vulgaris temporarily produced pemphigus like lesions(24). All these 
above evidence points towards the pathogenicity of these intercellular desmoglein 
antibodies. These pathogenic circulating intercellular desmoglein antibodies are 
diagnostic of pemphigus vulgaris and its titres correlated well with disease activity(9). 
And they are found in 80% of patients with active disease. There is evidence of presence 
of tissue fixed intercellular antibodies in lesions and adjacent healthy skin in about 90% 
of patients. Pemphigus vulgaris autoantibodies are usually of  IgG type but at times IgM, 
IgA, and the complement protein C3 might also be present. IgG4 is the predominant 
subtype of IgG seen in active pemphigus(25). The well identified keratinocyte antigens 
are desmosomal molecules called desmosomal cadherins, desmoglein3 (Dsg3) of 
130KDA and desmoglein1 (Dsg1) of 160 KDA molecular weight.  
Desmosomes: 
Desmosomes are discoid intercellular junctions of diameter 0.2 to 0.5micromteter. It 
consists of two electron dense plaque in each of the two adjacent cells and an intercellular 
cleft which separates the cells(26). These electron dense plaque consists of outer dense 
and inner less dense plaque which is anchored to the intermediate filament cytoskeleton. 
Adaptor proteins of aramidallo and plakin families anchor desmosomal cadherins to 
intermediate filament cytoskeleton(26). Desmosomal cadherins are transmembrane 
glycoproteins belonging to cadherin superfamily which are calcium dependant. The 
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intercellular adhesive interface is formed by desmosomal cadherins. The structure of 
desmosome is depicted in figure 1. 
 
Figure 1 Molecular model of desmosome(26). 
Pemphigus antibodies binds to the aminoterminal of the extracellular domain of the 
desmosomal cadherin(26). On binding of antibodies to desmosomal cadherins, there is 
increase in intercellular space and decrease and eventual disappearance of desmosome  
leading to rounding up of cells and detachment from one another without cell death. This 
process is called acantholysis(13). The process of  loss of adhesion between keratinocytes 
known as acantholysis is the basic abnormality found in pemphigus vulgaris. Primarily 
there is dissolution of intercellular adhesion substance resulting in separation of 
desmosomes(13).The process of acantholysis ultimately leads to the formation of bulla 
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within the epidermis. Pemphigus antibodies do not require complement to induce blisters 
in the skin. 
There are various proposed mechanisms of acantholysis described in pemphigus vulgaris. 
The exact process by which acantholysis occurs in pemphigus vulgaris is still unclear. 
Following are the various hypothesis concerning the pathogenesis of pemphigus vulgaris.  
Mechanism of acantholysis:  
1) Plasminogen activation - Activation of plasminogen activator leads to the 
formation of plasmin which induces cell adhesion dissociation(2)(26). 
2) Stearic hindrance - It is the direct inhibition of aminoterminal of extracellular 
domain of demosomal cadherins by pathogenic pemphigus antibodies(2)(26)(27)  .
The extracellular domain of desmosome is involved in transinteraction of 
desmosomal cadherins. However, desmosomal separation is not the primary event 
but collapse of cytoskeleton and shrinkage of keratinocyte precedes acantholysis. 
3) Phosphorylation of keratinocytes - Another hypothesis is that binding of 
pemphigus vulgaris antibody to the antigen activates  a variety of  intracellular 
signaling pathways leading to phosphorylation of keratinocyte proteins which 
leads to cellular dissociation(15). P38 mitogen activated protein kinase 
(P38MAPK) inhibitors prevents acantholysis in mice. 
4) Apoptosis – An earlier hypothesis had mentioned apoptosis of keratinocytes via 
FAS ligand pathway resulting in acantholysis. This was later disproved in that 
apoptosis was not a prerequisite but occurs secondary to acantholysis(28)(29). 
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5) Basal cell shrinkage hypothesis – Pathogenic autoantibody in pemphigus vulgaris 
binds to the receptor on keratinocytes and triggers a series of signal transduction 
pathways thereby resulting in rupture of cytoskeleton and collapse and shrinkage 
of basal keratinocytes while the keratinocytes in the suprabasal layer remain 
intact(29). 
6) Apoptolysis – This is the recent theory behind the pathogenesis of skin blistering 
in pemphigus. It links apoptotic pathway to suprabasal acantholysis and basal cell 
shrinkage resulting in tomb stone appearance of basal cells(29–31). It constitutes 
five consecutive steps(30). 
a) Pemphigus autoantibodies binds to its antigens (desmoglein and nondesmoglein 
antigens) on the keratinocyte cell surface. b) Increase in intracellular calcium, 
activation of cell death cascades and activation of EGF receptor, Src, mTOR, p38 
MAPK and other intracellular signaling elements. c) Early acantholysis  due to 
shrinkage of basal cells which is due to collapse and retraction of tonofilament and 
clumping of tonofilament in the perinuclear region by executioner caspases. d) 
dissociation of desmosomal adhesions occurs due to phosphorylation of 
desmosomal molecules and cleavage of cytoplasmic tail of desmoglein by the 
same cell death enzymes. This inside out responses leads to internalization of extra 
desmosome while the established desmosomes continues to link the shrinking 
basal keratinocytes. e) Advanced acantholysis leads to continued degradation and 
cleavage of cellular protein by the same enzymes resulting in complete separation 
of desmosomes by shear forces from the collapsing cell thereby stimulating 
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secondary antibody production against the desmosomes. f) Rounding up and death 
of acantholytic cells. There is irreversible damage to the mitochondria and nuclear 
proteins(30). 
The process of apoptolysis is depicted in the figure 2 and figure 3 given below. 
 
Figure 2 Current concept of acantholysis. PERP – peripheral myelin protein, EGF – 
epidermal growth factor, MAP – mitogen activated protein kinase(31)(32). 
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Figure 3 Hypothetical scheme of apoptolysis in pemphigus vulgaris(32). 
 
In pemphigus vulgaris, the pathogenic antibodies IgG is targeted against various types of 
keratinocyte surface antigens leading to the formation of suprabasal bulla by the process 
of apoptolysis . 
The different clinical phenotype noted in patients of pemphigus vulgaris and pemphigus 
foliaceous is explained by desmosomal compensation theory. Mahoney et al. have 
confirmed desmoglein compensation hypothesis  by showing that in wild type neonatal 
mice both anti Dsg 3 and anti Dsg1 antibodies are required to induce skin blisters(33). 
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Desmosomal compensation theory: 
Desmoglein 3 is present predominantly over suprabasal epidermis and is less in 
superficial epidermis whereas Dsg1 is distributed throughout epidermis but more over 
superficial layers of epidermis. In oral mucosa Dsg3 is distributed throughout epidermis 
while Dsg1 is poorly distributed. These desmogleins are found to compensate the 
functional loss of other desmoglein. This desmoglein compensation theory explains why 
pemphigus vulgaris with  only Dsg 3 antibodies has only mucosal involvement whereas 
patients with both Dsg1 and Dsg3 antibodies develop both cutaneous and mucosal 
lesions(26)(32)(33).The desmosomal compensation theory  is depicted in figure 4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
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Figure 4 Logical explanation of localization of blister in pemphigus by desmoglein 
compensation theory(27). 
Stanley et al. concluded that anti Dsg1 and Dsg3 antibodies are sufficient enough to 
induce blisters in pemphigus vulgaris patients. But in occasional cases it is observed that 
there is inconsistensies between desmoglein titres and the clinical phenotype of 
pemphigus.  
Following are the inconsistencies observed and questions raised regarding the 
pathogenicity of desmoglein antibodies in pemphigus vulgaris patients.  
1) Desmoglein1 and Dsg3 antibodies present in pemphigus vulgaris patients causes 
suprabasal rather than subcorneal and suprabasal blisters. 
2) Some individual harbor both Dsg1 and Dsg3 antibodies but do not manifest 
pemphigus. 
3) Kricheli et al. observed the presence of anti desmoglein antibodies in disease free 
relatives of pemphigus patients and only in 62% of  pemphigus vulgaris patients(34).  
4) Sera of patients with periodontitis and silicosis developed both anti Dsg1 and anti 
Dsg3 antibodies(35). 
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The following observations suggest that nondesmoglein antigens may be responsible for 
blistering in pemphigus vulgaris: 
1. High titres of desmoglein 3 antibodies were found to be present in the first degree 
relatives of pemphigus patients but apparently failed to produce blisters unlike in 
pemphigus patients(36).  
2.Pemphigus vulgaris autoantibody IgG representing extracellular domain of Dsg3, when 
injected into neonatal mice showed signs of cell-cell detachment visible on microscopy 
failed to produce gross skin blistering even though appreciable titre of antibody was 
present in mouse serum(37). 
3.Cholinergic agonists reversed acantholysis  both in vivo and in vitro(38). 
There has been always a correlation between disease severity and desmoglein antibody 
titres, but however in some cases of pemphigus, it doesn’t strictly correlate. Furthermore, 
anti desmoglein antibodies can be absent during the active stage of disease but can be 
present during remission, in patients with other medical conditions and also in healthy 
people. The above data suggests that desmoglein antibodies and nondesmoglein 
antibodies together mediate the pathogenicity of pemphigus vulgaris. Nguyen et al. 
concludes that the missing component in the pathogenesis is the antibodies to cholinergic 
receptors on the surface of the keratinocytes(39). 
Antibodies other than desmoglein postulated in pemphigus: 
Nguyen et al. reported that pemphigus vulgaris autoantibodies with anti Dsg 3 activity 
and absent Dsg1 activity can induce blisters in Dsg 3 deficient mice(40). This observation 
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led to detection of multiple non desmoglein antigens by probing immunoblots of 
epidermal extracts using pemphigus vulgaris sera.  Grando and colleagues proposed 
unifying hypothesis which states that blistering in pemphigus vulgaris is the result of 
synergy between anti-cholinergic receptor antibodies and anti-desmoglein antibodies(41).   
Facts in favour for pathogenic roles for nondesmoglein antibodies to keratinocyte 
receptor 
1) Nguyen et al. detected cholinergic receptor antibodies by radioimmunoprecipitation 
assay in 85% of pemphigus vulgaris and pemphigus foliaceous patients(42).  
2) Nguyen et al. observed acantholysis in keratinocyte monolayers of human skin 
induced by anti-α9 antibody(43).  
3) Nguyen et al. observed shedding of desmosomes by anti pemphaxin antibody and its 
adsorption prevented acantholysis by pemphigus vulgaris IgG. He also postulates that 
preabsorbed serum restores its acantholytic activity after addition of anti pemphaxin 
antibody(44). 
4) Grando reviewed the pathogenesis of pemphigus and concludes that cholinergic 
receptor antogonists causes acantholysis in keratinocyte monolayers whereas 
cholinomimetics restores acantholysis and counteracts pemphigus vulgaris IgG 
acantholytic activity in vitro and hence cholinomimetics are used in the treatment of 
pemphigus in vivo(45). 
5) Hu et al. observed that abnormal intracellular calcium concentration resulted in 
acantholysis in Hailey Hailey disease which is due to mutation in the gene ATP2C1. 
Sakunthabai et al. observed acantholysis in Dariers disease due to abnormal intracellular 
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calcium concentration as a result of mutation in the gene SERCA type2, 
ATP2A2(46)(47).  
By radioimmunoprecipitation assay using acetylcholine receptor derived from epidermal 
keratinocyte and covalently labeled with muscarinic radioligand as an antigen, Nguyen et 
al. detected that 85% of pemphigus patients have anti AChR antibody(43). He 
demonstrated that rDsg3-Ig-His adsorbs both desmoglein and nondesmoglein 
autoantibodies to various keratinocyte antigens. He also identified acetylcholine receptor 
antibodies targeted receptors by preincubating monkey esophagus with pemphigus 
vulgaris antibodies. Antibody to α9 acetylcholine receptor with both muscarinic and 
nicotinic actions stained keratinocytes in a fishnet pattern. Alpha 9 acetylcholine receptor 
antibodies induced pemphigus like acantholysis in keratinocyte monolayers. Acantholysis 
was reversed spontaneously or by cholinergic agonist carbechol.  
Acetylcholine receptors on keratinocytes: 
Epidermis has both muscarinic and nicotinic receptors(32)(48)(49). There are 5 types of 
muscarinic receptors M1, M2, M3, M4, M5 and 7 types of nicotinic receptors α3, α5, α6, 
α7, β1, β2, β4 in the epidermis. M3 is  predominantly situated in suprabasal layer,  M4 
and M5  in the prickle cell layer and M1 in superficial layer. Nicotinic receptors are 
present in suprabasal layer. Alpha9 acetylcholine receptor and pemphaxin are the recently 
described acetylcholine receptors in the pathogenesis of pemphigus. Alpha 9 
acetylcholine receptor is of both muscarinic and nicotinic type. Pemphaxin is a protein 
present on the keratinocytes and acts as cholinergic receptors by binding with 
acetylcholine. Pemphaxin is a homodimer with 40kDa subunits. All these acetylcholine 
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receptors helps in maintaining the shape and adhesion of keratinocytes. Muscarinic 
receptors exerts its action by releasing intracellular stores of calcium whereas nicotinic 
receptors does it by increase in the influx of calcium into the cell. 
Keratinocytes synthesize and release endogenous acetylcholine in a autocrine and 
paracrine manner. This endogenously produced acetylcholine constantly activates 
acetylcholine receptors to maintain the adhesive function of keratinocytes. Similarly both 
muscarinic and nicotinic agonists maintains the adhesive function of keratinocytes. 
Muscarinic or nicotinic antagonists like atropine and mecylamine respectively blocks 
acetylcholine receptors in the keratinocyte monolayers resulting in pemphigus like 
acantholysis. Cholinergic agonists of both classes reverses acantholysis as well as 
protects keratinocyte monolayers from the acantholytic effects of pemphigus antibody. 
Thus all the above observations suggests that keratinocyte adhesion and motility 
controlled by endogenous acetylcholine is antagonized by pemphigus autoantibody by 
acting on the acetylcholine receptors on the surface of keratinocytes resulting in 
acantholysis. 
The mechanism by which acetylcholine receptor antibodies resulting in acantholysis is 
depicted below as schematic diagram.(fig.5) 
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Figure 5 Hypothetical scheme of the time course of pathobiologic events leading to 
acantholysis in pemphigus(32). 
1) In stage 1, anti acetylcholine receptor antibodies binds to its receptors on the 
keratinocytes and interferes with the physiologic control of intercellular adhesion and its 
polygonal shape. There is also initiation of programmed cell death and increased 
phosphorylation of adhesion molecules resulting in its dissociation. 
2) In stage 2, there is shrinkage of keratinocyte due to collapse of tonofilament resulting 
in sloughing of desmosomes thereby stimulating secondary antibody production against 
desmosomal antigens. 
3) In stage 3, anti desmoglein antibodies binds to keratinocytes and prevents the 
formation of new desmosomes.  
Grando hypothesized that several acetylcholine receptor autoantigens are involved in the 
pathogenesis of pemphigus patients. Grando detected two cholinergic receptors in most 
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of the pemphigus vulgaris patients. The two receptors involved in the pathogenesis of 
pemphigus patients were α9 acetylcholine receptor and pemphaxin which is  a novel 
keratinocyte annexin like molecule that binds to acetylcholine(40).  
In neonatal mice, the pathogenicity of pemphigus sera is depleted by preabsorbing the 
pemphigus sera with pemphaxin. Antibody directed against pemphaxin caused 
acantholysis in keratinocyte culture. However it is noted that the eluted material is not 
pathogenic and hence suggested that the antibody against pemphaxin is necessary but not 
sufficient to be pathogenic. The effect of corticosteroids on acantholysis in pemphigus 
vulgaris patients is by boosting the pemphaxin expression. 
Nguyen et al. reported a case of pemphigus vulgaris who improved with cigarette 
smoking thereby paving the way for the use of nicotinamide as steroid sparing agent(43). 
Grando postulated multiple hit hypothesis which states that acantholysis in pemphigus is 
due to antibodies against different keratinocyte antigens which includes regulatory 
molecule such as AChR and structural molecule such as desmosomal cadherin(12). 
There is still a debate that whether cholinergic receptor antibodies represent an 
epiphenomenon secondary to acantholysis or is it a pathogenic antibody involved in  
pemphigus patients. However identification of antigens targeted by PV autoantibodies is 
still under intense research.  
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Clinical features: 
Pemphigus vulgaris is clinically divided into 3 subgroups 1) Mucosal dominant type with 
mucosal lesions and minimal skin lesions 2) Mucocutaneous type with extensive 
cutaneous lesions with mucosal lesions 3) Cutaneous type PV without apparent mucosal 
involvement is observed as a rare clinical and histologic expression of pemphigus. This 
expression can be a transient phenotype that may develop from, or evolve into, other 
subtypes of pemphigus(50). In majority of pemphigus vulgaris patients, oral mucosal 
involvement is the initial manifestation(13). Oral lesions either precedes cutaneous 
lesions or may be the only manifestation. About 50% - 70% of pemphigus vulgaris 
patients presents with oral lesions. They present with non-healing  painful ulcerations in 
the mouth(13). The most commonest site of involvement are buccal mucosa and  palate 
followed by  labial mucosa and tongue(13). Oral erosions are usually multiple and of 
variable sizes with an irregular, ill-defined border(51). Extensive oral mucosal 
involvement results in severe pain and decreased oral intake. The diagnosis of pemphigus 
is considered in patients presenting with non-healing oral ulcers persisting for more than 
a month(13). Other mucosa which can be affected are nasal mucosa, conjunctiva, 
oesophagus, pharynx, larynx, anal mucosa, urethral mucosa, vagina, labia, cervix and 
penile mucosa. Involvement of throat is associated with difficulty in swallowing. 
Pemphigus vulgaris patients develop cutaneous lesions after few weeks to few months 
whereas there are occasional reports of some patients presenting with only cutaneous 
lesions without mucosal lesions. Predominant cutaneous sites of involvement are scalp. 
face, axilla, groin and pressure points. Usually upper torso and central portion of the body 
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is commonly involved. Cutaneous lesions comprises of clear fluid containing flaccid 
blisters on a normal or erythematous skin. These clear flaccid blisters later becomes 
haemorrhagic or turbid and spontaneously ruptures to form painful erosions which has 
the tendency to extend. These erosions later on becomes crusted, oozes and  bleeds. If left 
untreated cutaneous erosions extends and becomes widespread resulting in complications 
like secondary infection or metabolic disturbances or both leading to death. Though 
pruritus is not a common symptom of pemphigus patients, its presence indicates that 
disease is active and predicts relapse. Skin lesions usually heals with hyperpigmentation 
or acanthomata but without scarring. Acral involvement is rare but its presence denotes 
poor prognostic indicator of the disease(17). Unusual clinical manifestations of 
pemphigus vulgaris are 1) isolated crusted plaque  on face or scalp 2) paronychia 3) foot 
ulcers 4) dyshydrotic eczema or pompholyx and 5) macroglossia(51). There are certain 
clinical signs which are elicited bed side in pemphigus vulgaris patients and these signs 
are helpful to differentiate between intraepidermal and sub-epidermal bullous disorders. 
Nikolskiy sign:  
When a tangential pressure is applied with a finger pad or thumb to the margin of an 
erosion or bulla, it forms a erosion due to cleavage of upper layer of epidermis from 
lower layer of epidermis(31).This is known as marginal nikolskiy sign and is positive in 
pemphigus. If the same is elicited over a normal looking skin away from the erosion or 
bulla, then it is named as direct or distant nikolskiy sign. This is the first sign to disappear 
with treatment whereas its presence indicates disease severity. 
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The nikolskiy phenomenon: 
 It is the formation of bulla after some time instead of erosion when similar kind of 
tangential pressure is applied. 
The modified nikolskiy sign:  
It is the peripheral extension of bulla when vertical pressure is applied its surface and it is 
useful when no new bulla is available for biopsy. The newly formed bulla does not show 
re-epithelisation which is seen in older subepidermal bulla thus making it to appear 
intraepidermal. 
Bulla spread sign:  
It is also known as Lutz sign. It is elicited by first marking the margin of the bulla by pen 
and then exerting slow unilateral pressure by a finger which extends the bulla margin 
beyond the marked margin. In pemphigus the newly formed bulla has irregular and 
angulated border whereas it is uniform and rounded in subepiderma bulla. 
Asboe Hansen sign:  
It is applied if the bulla is smaller and tense bulla, pressure is applied vertically on the 
surface of the bulla.It is positive in all cases of pemphigus. 
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DIAGNOSIS: 
Diagnosis of pemphigus is based on clinical features, histopathology, DIF and  indirect 
immunofluorescence study. 
Tzanck test:  
This test is very useful in early lesions of oral pemphigus. It is a simple, cost effective, 
rapid bedside test to diagnose pemphigus. With the help of blade the roof of newly 
formed bulla is deroofed and fluid present in the bullous cavity is completely drained off 
and the base is scraped and made into a smear on a clean glass slide and stained with 
leishman stain. Slide is then viewed under microscope under oil immersion for the 
presence of multiple acantholytic cells. An acantholytic cell is a large round keratinocyte 
with hyperchromatic nucleus, absent nucleolus and peripheral rim of basophilic 
cytoplasm with a perinuclear halo(52)(53)(54). Two types of acantholytic cell was 
described by Desai and Rao. Type A cells has large noncondensed nucleus, fuzzy 
basophilic cytoplasm and a perinuclear halo whereas type B cells has condensed pyknotic 
nucleus and well defined eosinophilic cytoplasm(17). Depicted below is a picture of 
acantholytic cells. (fig. 6) 
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Figure 6 Tzanck smear showing acantholytic cells(31). 
Cell adherence is less characteristic sign in pemphigus vulgaris. “Sertoli rosette” is where 
a ring of lymphocytes surrounds a central epithelial cell. “Streptocytes” is formed by a 
chain of lymphocytes which adhere together by glue like material(52). 
Histopathology:  
Skin biopsy is done from a fresh vesicle. Early histopathologic changes are eosinophilic 
spongiosis followed by separation of suprabasal keratinocytes from the basal cells  
forming a suprabasal bulla which contains acantholytic cells. Basal cells lose their 
adherence with the neighbouring cells but remain attached to basement membrane thus 
appearing as “row of tomb stones”. Upper dermis contains mixed inflammatory infiltrate. 
The picture of histopathology of pemphigus vulgaris is given below.(fig.7) 
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Figure 7 Histopathology of pemphigus showing suprabasal bulla and row of tomb stone 
appearance(55). 
Electron microscopy:  
There is widening of intercellular space followed by splitting of desmosomes resulting in 
separation of keratinocytes. Tonofilaments were found to retract and clump around the 
nucleus and also there is disappearance of desmosomal plaques. 
Immunoflourescence staining: 
All pemphigus vulgaris patients have both skin fixed and circulating antibodies against 
keratinocyte surface antigens. About 90% of pemphigus patients have skin fixed 
intercellular antibodies are in both lesional and nonlesional adjacent healthy skin. The  
presence of intercellular tissue fixed antibodies are detected by DIF (direct 
immunofluroscence) and circulating antibodies in the serum is detected by IIF ( indirect 
immunofluroscence) 
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Direct immunofluorescence: 
DIF of peri-lesional skin: 
It is a reliable diagnostic tool for pemphigus vulgaris. It is a nonquantitative test. All 
pemphigus vulgaris patients have positive DIF of perilesional skin. This test helps to 
detect the presence of IgG and C3 bound to cell surface of keratinocytes in the 
perilesional skin because immunoreactants are absent in the lesional skin. IgG is 
deposited in the intercellular junctions of epidermal keratinocytes and thus gives a fishnet 
appearance in DIF of pemphigus vulgaris patients. Increased  complement levels or its re-
appearance indicated impending relapse(17). The picture of direct immunofluorescence 
of skin is given below.(Fig. 8)In some patients, DIF may remain positive for many years 
even after clinical remission. 
 
Figure 8 Direct immunofluroscence study of pemphigus vulgaris patient showing fish net 
pattern of deposition of intercellular IgG antibodies(15). 
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DIF of outer root sheath: 
Studies shows that DIF of outer root sheath of plucked hair can be used as tool for the 
diagnosis of pemphigus vulgaris. Epidermis continues as outer root sheath and so if DIF 
is positive in epidermis then it will also be present in the outer root sheath of plucked 
hair. In a Indian study of pemphigus vulgaris patients, it was found that 85% had DIF 
positivity of plucked hair. Thus it is a simple, non-invasive and specific test which can be 
used to monitor disease activity(17). 
Indirect immunoflouroscence: 
Indirect immunofluorescence assays detects circulating intercellular antibodies present in 
the patients serum using a substrate like monkey oesophagus, guinea pig oesophagus or 
human skin. Majority (80%) of pemphigus patients in active disease have circulating 
intercellular antibodies in their serum(55). If indirect immunofluorescence is negative in 
pemphigus patient, then test has to be repeated with another substrate. Certain amount of 
circulating antibodies are detected by indirect immunofluroscence  in patients  with 
fungal infections, burns, myasthenia gravis, drug reactions and inpatients with antibodies 
to ABO blood groups(15). Disadvantage of indirect immunofluroscence is that it does not 
helps to differentiate between pemphigus vulgaris and foliaceous(55). It remains positive 
for a long time after clinical remission even in patients without active lesions. It is a 
useful guide for monitoring therapy. Its titre correlated well with disease activity except 
in certain cases. Indirect immunofluroscence  performed with blister fluid showed similar 
results like IIF performed with serum. It is a non-traumatic and simple procedure useful 
in the diagnosis of pemphigus vulgaris(17). 
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ELISA assay of recombinant Dsg1and Dsg3: 
Enzyme –linked immunosorbent assay of recombinant Dsg1 and Dsg3 detects circulating 
IgG antibodies in the serum of pemphigus vulgaris patients. It is more sensitive and 
specific test used for the diagnosis of pemphigus vulgaris patients. It is a quantitative 
analysis of antibodies level whereas IIF is a semiquantitative test(9). There is increased 
levels of Dsg3 in pemphigus vulgaris patients with predominant mucosal lesions whereas 
Dsg1 is raised up in PV patients with mucocutaneous lesions. In an Indian study on 44 
pemphigus patients, it was concluded that desmoglein antibodies levels correlated well 
with disease severity. However a small proportion of cases did not correlate  because of 
the presence of  pathogenic antibodies to nondesmoglein molecules or intracellular 
domain of Dsg1 and Dsg3 which is undetected by Dsg1 and Dsg3 specific ELISA(9). In 
case of high antibody concentrations, the assay plates become saturated and so ELISA 
results are not quantitative. 
In a study by of 35 pemphigus patients done by Patsatsi et al. disease activity was 
measured by means of PDAI and ABSIS disease activity scoring and concurrently 
correlated with Dsg1 and Dsg3 antibodies levels. This study showed that Dsg1 antibodies 
titre correlated well with disease activity but Dsg3 antibodies titre did not correlate(56). 
About 27 pemphigus patients was included in an Indian study by Sharma et al. and 
disease activity was correlated with desmoglein 1 and 3 antibodies titre. It was concluded 
that desmoglein antibody titre correlated well with disease activity but its titres failed to 
correlate with its morphologic subtypes of pemphigus vulgaris(57). 
45 
 
Recently, new immunologic targets involved in pathogenesis of pemphigus vulgaris have 
been discovered which includes acetylcholine receptor. Various studies have been  
conducted to determine the relationship of development of pemphigus vulgaris and 
acetylcholine receptor antibodies. In one such study by Sanchez et al. in which he 
included 31 pemphigus patients and measured disease severity by BSA and correlated 
with desmoglein and acetylcholine receptor antibodies at the time of diagnosis and in the 
follow up. This study concluded that acetylcholine receptor antibodies correlated with 
disease severity at the time of diagnosis and follow up. But it is still not clear whether it 
is a potential trigger of pemphigus or just an epiphenomenon(11).  
Scoring systems in pemphigus: 
As patients with pemphigus present with various protean manifestations, there are various 
therapeutic options available with variable outcome. This led to the need for clinical 
scoring system to monitor the activity and its response to treatment. 
Pemphigus disease activity index: 
 Pemphigus disease area index scoring was developed by international pemphigus 
committee in 2007(8)(58). It assess both cutaneous and mucosal lesions, its number and 
sizes and also postinflammatory hyperpigmentation of resolving lesions(59). Many 
studies were conducted to validate scoring system. In one such study, PDAI scoring was 
compared to ABSIS and it was concluded that PDAI is quick, easy and reliable method to 
score both cutaneous and mucosal lesions(59)(8). Assessment of type of lesions, 
Nikolskiy sign or use of rule of nine is not required in PDAI scoring thereby eliminating 
the source of variability(8). The possible score of PDAI ranges from 0 to 263. Out of 263 
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points, 250 points denotes disease activity (120) points each for cutaneous lesions and 
mucosal lesions and 10 points for scalp lesions). Thirteen points was allotted to disease 
damage(58). 
Autoimmune bullous skin disorder intensity (ABSIS): 
 It is a quantity and quality based scoring for both mucosal and cutaneous lesions(59). It 
is also used for other immunobullous disorder. 
Saraswats oral pemphigus scoring: 
 It scores only mucosal lesions(59).  
Various other scoring system used for pemphigus includes Mahajan’s scoring system, 
Kumar’s scoring system and Harman’s pemphigus grading.  
 
Treatment: 
The main stay of treatment for pemphigus vulgaris is systemic corticotseroids. After the 
advent of steroids the mortality rate of pemphigus is reduced from 90% to 33%(60).  
Treatment of pemphigus is divided into 3 phases 1) control phase 2) consolidation phase 
3) maintenance phase(13).The main aim of treatment is bring the disease under control as 
early as possible. 
Control phase: 
 In this phase disease is brought under control by rapidly increasing the intensity of 
treatment until reduction or complete suppression of new lesion occurs, established 
lesions begins to heal. Pemphigus usually responds within 2 weeks. Initial dose of steroid 
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is 0.5mg to 1.5mg/kg/day(61). If the disease is not under control, then the dose of steroid 
is increased by 50% every 1-2 weeks until disease is controlled(13). 
Consolidation phase: 
In this phase the dose of steroid needed to control the disease is maintained until 80% of 
established lesions have healed(13). 
Maintenance phase: 
 This phase begins when most of the established lesions have resolved. In this phase the 
doses of steroid is tapered gradually to lowest dose to suppress the occurrence of new 
lesions(13). As higher and prolonged doses of steroid can have deleterious side effects, 
adjuvant drugs which have steroid sparing effect is added to the treatment. Some of the 
adjuvant drugs commonly used are 
1. Azathioprine in the dose of 1-3mg/kg/day. The levels of TPMT ( thiopurine 
methyl transferase activity) is measured before initiating treatment because the 
dose of azathioprine depends on it. If the TPMT activity is high, then patient is 
treated with normal doses of azathioprine 2.5mg/kg/day. If TPMT activity is low, 
then the dose of azathioprine is adjusted to low dose of 0.5mg – 1.5mg / kg / day. 
Absence of TPMT activity is an indication for avoidance of azathioprine(61). 
2. Mycophenolate mofetil 2g/ day. The dose of MMF is gradually increased by 
500mg every week until 2g/day is reached. 
3. Cyclophosphamide 2mg/kg/day or as DCP pulse (dexamethasone, 
cyclophosphamide pulse therapy) 
4. Methotrexate 10-20mg/week 
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5. Dapsone 100mg / day 
Other modalities of treatment include Intravenous immunoglobulin (IVIgG) and 
plasmapheresis. Localised lesions are treated with intralesional and topical steroids. Oral 
lesions are treated with topical steroid. In case of refractory cases biological treatment 
with humanized antiCD20 monoclonal antibody known as rituximab results in complete  
healing of all lesions(62). 
According to multiple hit theory, cumulative effects of nondesmoglein target antigen like 
acetylcholine receptor is necessary for the process of acantholysis(45). Studies also 
proved that titres of acetylcholine receptor antibodies correlated with disease activity and 
desmoglein titres. This led to the introduction of cholinomimetic drugs for the treatment 
of pemphigus vulgaris patients(11). To ameliorate the side effects of steroid, newer non-
hormonal treatment of pemphigus with cholinergic agonists was suggested. Grando, in 
his clinical trial on mestinon (pyridostigmine) in pemphigus patients demonstrated that 
mestinon can be used for mild disease with chronic lesions on limited areas(63). Nguyen 
et al. in his study concluded that pyridostigmine bromide (acetylcholine esterase 
inhibitor) helped to maintain steroid at a lower dose in pemphigus patients than before 
initiating pyridostigmine treatment(64). 
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MATERIALS AND METHODOLOGY 
Study design:  
It is a study of acetylcholine receptor antibodies done to correlate with disease activity 
measured by PDAI and to compare with desmoglein titres in pemphigus vulgaris patients. 
Setting:  
The study was conducted in the Outpatient Department of Dermatology, Venereology 
and Leprosy, Christian Medical College and Department of Biochemistry in a tertiary 
care hospital in South India. 
Duration of the study: 
 The study was conducted between period of October 2014 and August 2015(13 months). 
Study population:  
Inclusion criteria:  
All patients diagnosed to have pemphigus vulgaris based on clinical (presence of mucosal 
and/ or cutaneous erosions) and histological (intraepidermal or suprabasal acantholysis) 
or DIF (deposition of IgG and/or C3 between keratinocytes) and who consented to 
participate were included in the study.  
Exclusion criteria: 
Patients with Myasthenia gravis, Sjogrens syndrome and Thymoma were excluded from 
our study. 
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Methodology:  
All patients who conformed to the inclusion criteria were examined by the principal 
investigator after a written consent was obtained.(Annexure 1) Details on demography, 
duration of the disease, site of onset of lesion, duration and details of treatment taken 
were recorded in a proforma.(Annexure 2) Patients were categorised according to the 
clinical variants of pemphigus (pemphigus vulgaris, pemphigus foliaceous and 
pemphigus vegetans). Patients with PV were further categorised into variants as:- 
mucocutaneous, mucosal dominant or cutaneous dominant pemphigus. They were 
assessed at the time of their presentation for clinical severity of their disease with the help 
of PDAI clinical scoring.(Annexure 2) 
The PDAI score was calculated by assessing the number and the size of the lesions 
present on the skin, scalp and mucosa. The disease activity on the skin was calculated as 
the sum of the scores on 12 predetermined areas. The score on each area was graded as: 
0, 1, 2, 3, 5 and 10. The disease activity on the scalp was determined by the number of 
quadrants involved and was graded as 0, 1, 2, 3, 4 and 10. The activity on the mucosa 
was scored as: 0, 1, 2, 5 and 10 based on the number and size of the erosions on 12 sites. 
The damage score in each area was taken as 1 if resolving erythema/ hyperpigmentation 
was present and 0 if absent. 
Desmoglein1 and desmoglein3 antibody titre was evaluated by ELISA method for all the 
patients. Desmoglein estimation is done by M.B.L.Co.Lt desmoglein ELISA kit (Japan). 
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Readings more than 20u/ml is taken as positive titre. In addition to this, estimation of 
AChRAb titre was done by RSR’s AChRAb ELISA kit (RSR Limite78, Avenue Park 
Pentwyn Cardiff CF23 8HE, United Kingdom). The value AChRAb titre was correlated 
with disease severity and then compared with desmoglein antibody titre. 
Estimation of AChRAb titre: 
About 5ml of blood was collected in a vaccutainer test tube from the patients and 
transported immediately to biochemistry department for centrifugation and sera was 
stored at -20˙c in aliquots for analysis. At the time of analysis sera was removed from the 
refrigeration and thawed.  
 Assay Principle: 
RSR’s AChRAb ELISA depends on the ability of AChRAb in human serum to bind to 
similar sites on the AChR as various monoclonal antibodies such as MAB1(coated on 
ELISA plate wells) and MAb2 and or MAb3(which are labeled with biotin).In the 
absence of AChRAb a complex is formed between MAb1 coated on the plate wells, the 
AChR and MAb2- and MAb3-Biotin. MAb2- and MAb3- Biotin bound are then detected 
by addition of streptavidin peroxidase (SA-POD), which binds specifically to Biotin. 
Excess, unbound SA-POD is the washed away and addition of the peroxidase substrate 
3,3’,5,5’ – tetramethylbenzidine (TMB) results in formation of blue colour. This reaction 
is stopped by addition of stop solution causing the well contents to turn yellow. The 
absorbance of the yellow reaction mixture at 450nm is then read using an ELISA plate 
reader. In the presence of AChRAb the formation of the MAb1-AChR-MAB2 biotin 
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complex is inhibited, resulting in less SA-POD being bound and a reduction in final 
absorbance at 450nm. The higher the concentration of AChRAb in the test serum, the 
greater the inhibition of ACRAb in the test serum, the MAb-Biotin binding. The 
absorbance of each well is read at 450nm using an ELISA plate reader.. 
Result analysis: 
A calibration curve is drawn by plotting calibration concentration on the x-axis against 
the absorbance of the calibrators on the y-axis. The AChRAb concentrations in patients 
sera is then read off the calibration curve. The assay cut off value is < 0.45nmol/L for 
negative and ≥ 0.45nmol/L for positive patients. 
 Sample size: 
A sample size of 12 patients are needed to detect a correlation of 0.78 among disease 
extent and acetylcholine receptor antibody level with 80% power and 5% error. 
Following formula was used to calculate sample size. 
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Statistical analysis: 
The statistical analyses were performed using Windows Office Excel 2007 and SPSS 
12.00 for Windows. The continuous variables were summarised as mean with standard 
deviation or median with maximum and minimum values of the ranges. The categorical 
variables were summarised as numbers and percentages. The relationships between 
continuous variables were assessed using Pearson’s product moment correlation with 
scatter plots as diagrammatic representations of the correlation.  
Institutional review board:  
The study was approved by the Institutional review board. 
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RESULTS 
A total of 77 patients with pemphigus, who met the inclusion criteria were enrolled into 
the study during the study period of October 2014 to August 2015. 
Demographic details: 
Age distribution: The mean age of the study population was 46 years +/- 13years. The 
youngest patient was 22years old and the oldest patient age was 79years old. Maximum 
number of patients (70%) were more than 40yrs of age. This is depicted in figure 9. 
 
Figure 9 Distribution of patients by age and gender. 
Females: Females outnumbered males in all the age groups. There was an equal 
distribution of female participants (34%) in the age group of 22 - 30yrs and 31 – 40 yrs. 
Majority of female participants (66%) belonged to the age group of 41- 50yrs and above 
50 yrs. 
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Males: Majority of male patients 54.2% were more than 50 yrs old. There was only one 
patient in 22 – 30 yrs age group. 
Gender distribution of the patients: 
There were totally 53 females (68.83%) and 24 males (31.17%). The female to male ratio 
was 2.2:1. This is depicted in figure 10.   
 
 
 
Figure 10 Gender distribution in the study population. 
Duration of lesions:  
The duration of skin lesions ranged between 2-120 months and of that of oral lesions 
ranged from 2 – 210 months. The mean duration of skin lesions was 30.35 +/- 35.95 
months and median duration was 12 months. The mean duration of oral lesions was 32.9 
+/- 36.79 months and median duration was 24 months. 
Females 53,68.83%  
Males 24, 31.70% 
Gender distribution 
Female Male
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Onset of lesions: 
At presentation 24 of 77 patients (31.2%) had both cutaneous and oral lesions, 19 had 
only cutaneous lesions (24.7%) and 15 had only oral lesions (19.5%). The most common 
site of onset of cutaneous lesion was chest. Similarly, the most common site of onset of 
oral mucosal lesion was buccal mucosa. 
Clinical subtypes of pemphigus vulgaris: 
 
Figure 11 - Distribution of clinical subtypes of pemphigus vulgaris in the study 
population. 
The figure 11 shows the distribution of the subtypes of pemphigus vulgaris in the study 
population. Majority (73%) of patients with PV had mucocutaneous involvement. About 
20% of the population had purely mucosal and 6% had predominantly cutaneous disease.  
mucocutaneous 
56,  73.30% 
cutaneous 6, 
6.67% 
mucosal 15, 20% 
Distribution of subtypes of pemphigus vulgaris 
mucocutaneous cutaneous mucosal
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Distribution of oral mucosal lesions: 
 
 
 
Figure 12 - The piechart shows the distribution of oral mucosal lesions in both mucosal 
and mucocutaneous subtype of pemphigus patients. 
 
The chart (fig.12) shows majority of patients (46.8%) had buccal involvement followed 
by tongue, palate, labial and gingiva. Other mucosa involved were nasal and genital 
mucosa in 3 patients each. 
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PDAI clinical scoring for disease activity: 
 
 
Figure 13 - PDAI clinical severity scores of skin, mucosa, scalp and total score 
The graph (fig.13) shows the minimum, maximum and mean value of PDAI score of 
skin, mucosa, and scalp.  
 The minimum score is zero for all the sites.  
 The maximum score for total skin was 50 out of 132 and the mean was 5.3 +/- 8.6.  
 The maximum score for total scalp was 10 out of 11 and the mean was 1.08 +/- 
2.08. 
 The maximum score of mucosa was 22 out of 120 with a mean of 4.44 +/- 6.4. 
 The maximum PDAI total score was 82 out of 263 with a mean of 10.82 +/- 13.16. 
 PDAI score was zero in 19 patients who were in clinical remission. 
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 There were 16 patients (20.8%) who presented with only mucosal lesions. 
 Forty two patients (54.5%) presented with both mucosal and cutaneous lesions. 
Grading of PDAI score: 
 
Figure 14 - The  pie chart depicts the grading of disease according to PDAI score. 
The chart (fig.14) shows that there were about 42 patients (54.5%) with mild disease, 26 
patients (33.8%) with moderate disease and only 9 patients (11.7%) with severe disease 
Tzanck smear: 
Tzanck smear done from a vesicle or an erosion was positive for acantholytic cells in all 
the patients studied. 
Direct immunofluroscence test: 
Direct immunofluroscence test of the perilesional skin was done in all the patients and all 
of them showed IgG and C3 deposition in the intercellular region of lower epidermis with 
fish net appearance.  
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Treatment: 
Majority of the study patients (72 patients), at presentation to our hospital were already 
on treatment. Among patients on treatment, 69 of them were on oral steroid therapy. 
Twenty patients were on steroid monotherapy. The range of daily dose of steroid varied 
from 10mg to 80mg.The mean daily dose of oral steroid was 12.7mg +/- 9.9. 
 
Figure 15 - Treatment at inception into the study  
The chart (fig. 15) shows that majority of the patients (52 patients) were on other 
adjuvant drugs as well. 
The adjuvant drugs used were 
Azathioprine – 47/77 (61%), maximum dose – 150mg, mean dose – 45.11mg +/- 
17.07mg. 
Dapsone – 3/77 (4%), maximum and mean dose – 100mg 
Mycophenolate mofetil – 1/77 (1%) 
Cyclophosphamide – 1/77 (1%) 
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Range of desmoglein titres: 
 
Figure 16 - Range of Dsg1 and Dsg3 titres. 
Dsg1titres:- The graph (fig. 16) shows that the titres of desmoglein 1 ranged from 
minimum of 2 to maximum of 234 with a mean value of 67.1 +/- 70.8. The cut off value 
taken for the diagnosis of pemphigus vulgaris for both Dsg1 and Dsg3 titre was 20 u/ml. 
About 33 patients had low Dsg1 titres, among them 24 patients were in clinical remission 
and 8 of them had only mucosal lesions. 
Dsg3 titres:- The graph (fig.15) shows that the titres of desmoglein 3 ranged from 
minimum of 2 to maximum of 220 with a mean value of 116.7 +/- 69.3. Desmoglein 3 
titres of 12 patients (15%) were less (<20u/ml) than the cut off value. Of the patients with 
low Dsg3 values, 9 patients were in clinical remission and 3 patients had only cutaneous 
lesions. 
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Distribution of Dsg1 and Dsg3 titre in the study population: 
 
 
 
Figure 17 Distribution of Dsg1 in the study population. 
The graph (fig.17) shows distribution of Dsg1 titres in the study population. Majority of 
them had low Dsg1 titres (<25u/ml) in the study population. It ranged from minimum of 
0 to maximum of 234 u/ml. 
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Figure 18 Distribution of Dsg3 in the study population. 
The graph (fig.18) shows that most of the study population had high titres of Dsg3 
(>100u/ml). There were 65 patients with positive Dsg3 titre, out of which 45 patients had 
Dsg3 value of more than 100 u/ml  
 
Severity of the disease and the mean value of Dsg1 and Dsg3: 
Grading of PDAI 
score 
Mean value of Dsg1 
antibody u/ml 
Mean value of Dsg3 
antibody u/ml+/-SD 
Gender distribution 
Male : female 
Mild  41.7 +/-60.5 91.9 +/-67.7 13:29 
Moderate  97.4 +/-73.9 135.9 +/-63.9 10:16 
Severe  109.18 +/-55.6 179.2 +/-22.4 1:8 
 
Table 1 Shows the mean value of Dsg1 and Dsg3 antibody and its gender distribution in 
mild, moderate and severe disease. 
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As depicted in table 1 there is female preponderance in all the severity group of diseases. 
The mean value of Dsg1 and Dsg3 is increasing according the severity of disease. 
 
Clinical subtypes of pemphigus vulgaris and its Dsg titres: 
 
  
 
Figure 19 - Distribution of Dsg1 and Dsg3 titres in the clinical subtypes of pemphigus 
vulgaris. 
Mucocutaneous subtype(n=56): 
 The bar chart (fig.19) shows that in mucocutaneous type of pemphigus vulgaris, 
 31patients (64.6%) had raised titres for both Dsg1 and Dsg3, 
 15 patients(31.3%) had elevated titres of only anti Dsg3 antibody, 
 Isolated anti Dsg1antibody titre was raised in 2 patients (4.2%). 
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Mucosal subtype(n=15): 
The bar chart (fig.19) shows that in mucosal subtype of pemphigus vulgaris, 
 8 patients (57.2%) showed raised titres of anti Dsg3 antibody alone, 
 Both Dsg1 and Dsg3 antibody titre was raised in 6 patients(42.9%), 
 None of the patients were found to have raised anti Dsg1 antibody titre. 
Cutaneous subtype(n=6):  
The bar chart (fig.19)  shows that in cutaneous subtype of pemphigus vulgaris, 
 2 patients had raised titres of both anti Dsg1 and anti Dsg3 antibody titre, 
 One patient each had isolated raised titres anti Dsg1 and anti Dsg3 antibody titre. 
Mean value of anti Dsg3  and Dsg1 antibody titre in different subtypes of pemphigus is 
depicted in table.2and table.3 
Subtype of pemphigus Mean value anti Dsg3 
antibody (u/ml) +/-SD 
        
 
   p-value -  0.0224 Mucocutaneous  123.5 +/-67.9 
Mucosal  127.0 +/-62.2 
Cutaneous  28.8 +/-37 
 
Table -2Shows the mean value of anti Dsg3 antibody among subtypes of pemphigus. 
The table (Table 2) shows that the mean value of anti Dsg3 antibody titre was raised in 
mucocutaneous and mucosal type of pemphigus with a p-value of 0.0224 which is 
statistically significant. 
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Subtype of pemphigus Mean value anti Dsg1 
antibody (u/ml) +/-SD 
 
 
p - value – 0.2075 Mucocutaneous  66.28 +/-68.4 
Mucosal  54.03 +/-78.1 
Cutaneous  106.6 +/-71 
Table -3 Shows the mean value of anti Dsg1 antibody among subtypes of pemphigus. 
The table (Table 3) shows that the mean value of anti Dsg1 antibody titre is raised in 
cutaneous type of pemphigus when compared with mucocutaneous and mucosal 
subtypes. But this did not reach the level of statistical significance (p-value=0.20).  
 
Figure 20 Histogram depicting distribution of Dsg1 in the study population. 
The histogram (fig:20) does not follow a normal curve. It denotes that there is 
predominance of low titre of Dsg1 in the study population 
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Figure 21 Histogram depicting distribution of Dsg3 titre in the study population 
The histogram (fig. 21) does not follow a normal curve. It denotes that there is 
predominanace of high titre of Dsg3 antibody in the study population. 
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Correlation PDAI score with anti Dsg1 titres in the study population: 
 
Figure 22 Scatter plot compares total PDAI score with anti Dsg1 titre. 
Table 4 Spearman’s correlation of coefficient of anti Dsg1titre with PDAI score.    
  PDAI 
Dsg1 Correlation coefficient 0.4 
 p-value <0.01 
 
The scatter plot (fig.22) and table 4 compares PDAI score with anti Dsg1 antibody titre 
and shows a correlation co-efficient of 0.4 and p-value of <o.o1 which is statistically 
significant. There is a rising trend in the scatter plot as the PDAI score and Dsg1 titre 
increases. 
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Correlation PDAI score with anti Dsg3 titres in the study population: 
 
Figure 23 Scatter plot compares PDAI score with Dsg3 titres in the study population. 
 
  PDAI 
Dsg3 Correlation coefficient 0.43 
 p-value <0.01 
 
Table 5 Spearman’s correlation coefficient of anti Dsg3 titre with PDAI score. 
The scatter plot (fig.23) and table 5 shows the comparison of anti Dsg3 antibody titre 
with PDAI total score and has a correlation coefficient of 0.43 and a p-value of <0.01 
which is statistically significant. The scatter plot shows a rising trend as the titre of Dsg3 
and PDAI score increases. 
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Acetylcholine receptor antibody titre: 
There were a total of 17 patients (22%) with raised AChRAb titre. The prevalence of 
AChRAb in our study population was 22%.               
 
Characteristics of AChRAb positive patients: 
S.No. Age in 
years 
Sex  Duration 
of illness 
in months 
Subtype PDAI 
total 
score 
On treatment at 
presentation 
Dsg1 and Dsg3 
1 31 F 12months mucocutaneous 10 yes ↑Dsg3 
2 79 M 1month mucocutaneous  15 yes ↑Dsg1  
and Dsg3 
3 40 F  18 months mucocutaneous 38 yes ↑Dsg1 and Dsg3 
4 45 F 96 months Cutaneous  8 yes ↑Dsg1 
5 49 F 96 months mucocutaneous 11 yes ↑Dsg1 and Dsg3 
6 56 F 1 month mucocutaneous 46 no ↑Dsg1 and Dsg3 
7 43 M 36 months mucosal 13 yes ↑Dsg1 and Dsg3 
8 51 F 60 months mucocutaneous 4 yes ↑Dsg3 
9 47 M 1month mucocutaneous 17 yes ↑Dsg1 and Dsg3 
10 64 M 12 months mucocutaneous 3 yes ↑Dsg3 
11 23 F 36 months mucocutaneous 0 yes ↑Dsg1 and Dsg3 
12 34 M 96months cutaneous 9 yes Negative 
13 70 F 60 months mucosal 0 yes ↑Dsg3 
14 56 F 24 months mucocutaneous 0 yes ↑Dsg3 
15 54 M 72months mucocutaneous 1 yes ↑Dsg3 
16 46 F 36 months mucocutaneous 0 yes ↑Dsg3 
17 31 M 4months mucocutaneous 21 yes ↑Dsg1 
Table 6 Shows the characteristics features of AChRAb positive patients. 
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The table 6 shows the characteristic features of AChRAb positive patients. There were 13 
patients of age >40yrs. The duration of illness ranged from minimum of 1 month to 
maximum of 96 months. All the patients were on treatment at the time of presentation 
except one patient. All the AChRAb positive patients had raised titres of either Dsg1 or 
Dsg3 except one. 
 
Gender distribution among positive patients: 
 
Total number of patients 17 
Male 7 
Female 10 
 
Table. 7 Gender distribution in AChRAb titre positive patients. 
The table (table.7) shows the gender distribution among AChRAb titre  positive patients 
with female preponderance.  
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Range of acetylcholine receptor antibody titre in the positive patients: 
 
Figure 24- Range of AChRAb titre in the positive patients. 
The graph (fig.24) depicts the range of AChRAb titres in the positive patients. The range 
varied from a minimum of 0.5nmol/l to a maximum of 4.0nmol/l. The minimum cut off 
value for acetylcholine receptor antibody titre was taken as ≥0.45nmol/l The mean value 
of AChRAb titre is 2.06nmol/l +/- 1.1nmol/l.  
Among AChRAb titre positive patients, 13 patients were of mucocutaneous type and 2 
each of mucosal and cutaneous type. 
Subtypes in AChRAb positive patients: 
Subtype of pemphigus Mean (nmoles/l)+/-SD 
Mucocutaneous – 13/17 2.2 +/-1.1 
Mucosal – 2/17 2.6 +/-0.7 
Cutaneous – 2/17 0.8 +/-0.4 
 
0.5 
4 
2.06 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5 Range of AChRAb titres 
minimum
maximum
mean
73 
 
Table.8 Mean value of AChRAb titre in subtypes of pemphigus vulgaris patients. 
The table.8 depicts the mean value of AChRAb titre among positive patients. 
Grading of disease severity and corresponding mean value: 
Severity of disease Mean (nmoles)/l) +/-SD 
Mild – 8/17 2.4+/-1.0 
Moderate – 7/17 1.9+/-1.2 
Severe – 2/17 1.1+/-0 
 
Table.9 Mean value of AChRAb titre  and disease severity. 
The table.9 portraits the mean value of AChRAb titre and disease severity. Among 
AChRAb titre positive patients, 8 patients had mild disease, 7 patients had moderate 
disease and 2 patients had severe disease. 
AChRAb positive patients and their desmoglein titres: 
Among AChRAb positive patients, there were 7/17 patients (10.4%) with elevated titres 
of Dsg3 antibody and 8/17 patients with elevated titres with both Dsg1 and Dsg3 
antibody titre. Isolated raised Dsg1 titre was seen only in one patient with AChRAb 
positivity. 
  PDAI Dsg3 Dsg1 
AChRAb Correlation 
 co-efficient 
 
0.03 
 
0.025 
 
0.09 
                      
p-value       
 
0.76 
 
0.52 
 
0.7 
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Table.10 Spearman’s correlation coefficient of AChRAb titre with PDAI score, anti Dsg1 
and anti Dsg3 titre 
The table.10 depicts the correlation of AChRAb titre with PDAI total score, anti Dsg1 
antibody titre and anti Dsg3 antibody titre. This was not statistically significant. 
 
CLINICAL PHOTOGRAPHS OF PEMPHIGUS VULGARIS PATIENTS 
 
 
Figure. 25 Crusted erosions over chest, neck and abdomen, (PDAI - 42). 
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Figure. 26 and 27 Crusted erosions over chest, abdomen, back and upper extremity, 
(PDAI - 35). 
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Figure. 28 Erosion with re-epithelialisation and acanthoma,(PDAI - 30). 
 
 
Figure. 29 Erosion over periocular, perioral, labial and palatal mucosa. 
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Figure. 30 Crusted erosion over scalp. 
 
 
Figure. 31 Erosion over buccal mucosa. 
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Figure. 32 Reagents used in AChRAb ELISA kit 
 
 
 
Figure. 33 AChRAb ELISA plate with samples. 
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DISCUSSION 
Pemphigus vulgaris is a chronic autoimmune intraepidermal bullous disorder. The 
incidence rate of pemphigus vulgaris among dermatology outpatient attendees in India is 
0.09% - 1.8%(3)(18). Clinically pemphigus is characterised by flaccid blisters and 
erosions of skin and mucosa. Autoantibodies directed against desmoglein adhesion 
molecules, Dsg1 and Dsg3 leads to detachment of keratinocytes in the epidermis 
resulting in the process of acantholysis. Stanley et al. reports that these anti desmoglein 
antibodies are sufficient for the formation of blisters in pemphigus patients(12). Mahoney 
et al. and Udey et al. also states that both Dsg1 and Dsg3 antibodies are essential for the 
process of acantholysis in pemphigus(12). Kumar et al. estimated Dsg1 and Dsg3 
antibodies titres by ELISA method and correlated it with disease severity(9). He observed 
high titres of Dsg3 in patients with severe oral mucosal involvement and  high titres of 
Dsg1 in case of cutaneous involvement regardless of type of pemphigus(57). But 
majority of patients in remission also had high titres of Dsg3 antibody. This points out 
that the estimation of titre of pathogenic IgG subclass is more valuable in assessing the 
disease severity instead of whole of IgG titre. He also observed low titres of Dsg1 and 
Dsg3 in clinically active pemphigus(17). This was explained due to the presence of 
pathogenic antibodies against non desmoglein antigens or against the intracellular domain 
of Dsg1/Dsg3 which is undetectable by ELISA kit. Grando et al. recently listed a group 
of autoantigens which includes adhesion molecules (Dsg1, Dsg2, Dsg3), plakoglobulins, 
desmocollins, BP180 and receptor molecules like alpha9 AChR, alpha3 AChR, 
pemphaxin and other annexins, FcєRIα to be involved in the pathogenesis of 
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pemphigus(45). In addition Nguyen et al. concluded that antibodies against non 
desmoglein antigens on the surface of keratinocytes can induce pemphigus vulgaris like 
lesions(12). These non desmoglein antibodies were identified as acetylcholine receptor 
antibodies involved in regulation of keratinocytes.  Identification of these antigens led to 
the search of novel therapies like cholinomimetics to ameliorate the side effects of 
corticosteroid. Grando and Dahl observed antiacantholytic effect of cholinomimetics on 
keratinocytes in vitro(12)(65).There is only a single published study on correlation of  
acetylcholine receptor antibodies with desmoglein titres and pemphigus disease 
severity(66). There are no published data on acetylcholine receptor antibody in 
pemphigus from India.  
Hence, we studied the correlation of disease severity with titres of acetylcholine receptor 
antibodies and desmoglein titres in pemphigus patients attending our hospital. Pemphigus 
disease area index clinical score was used to quantify the disease severity. The diagnosis 
of pemphigus was made based on clinical features, classical histopathological finding of 
suprabasal bulla and direct immunofluroscence of the perilesional skin showing IgG and 
C3 deposition in the intercellular region of epidermis having a fishnet pattern. Seventy 
seven pemphigus patients who attended the dermatology department with either active 
disease or in remission during the study period, were included in the study.  
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Demographic profile: 
Age of the patient at presentation: 
Majority of the patients (70%) were above 40 yrs which is similar to that of other 
studies(67)(68). However, the data from India showed a different trend. Mascarenhas et 
al. and Singh et al. observed that more than 50% of pemphigus patients were seen below 
the age of 40yrs(17)(18). 
The mean age of onset of the disease in our patients studied was 46yrs. Similar 
observation was seen in other studies, where the mean age of presentation of pemphigus 
vulgaris was above 40 yrs.(69–71) The youngest patient in our study was 22yrs old and 
the oldest was 79yrs old.  
Gender distribution: 
The male:female ratio in our study was 1:2.2 with female preponderance. Similarly 
female preponderance was observed in other studies too(69–72). However, some studies 
showed a male preponderance(3)(18)(73). 
Duration of disease: 
The average duration of disease ranged from minimum of 2 months to 18 yrs. 
Site of lesion: 
The commonest site of onset of cutaneous involvement was the chest and buccal mucosa 
was the commonest mucosal site of onset in our patients. 
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In the oral cavity, majority of patients (36 patients) had buccal mucosal involvement 
followed by tongue, palate, labial and gingiva. Oral lesions are most common at the site 
of frictional trauma like buccal mucosa followed by  tongue, palate and labial 
mucosa(71). Other mucosa involved were nasal and genital mucosa in 3 of our patients. 
Clinical subtype of pemphigus: 
The commonest subtype of pemphigus vulgaris seen in our study population was 
mucocutaneous type (73%). This was followed by mucosal (15%) and cutaneous (5%). 
This is in concordance with other studies, in which they observed more than 50% of 
patients with mucocutaneous type of pemphigus vulgaris(1)(74)(75). Kavusi et al. in his 
retrospective study has found that mucocutaneous subtype of pemphigus patients  has a 
lower rate of remission and frequent rate of relapses(76). 
Pemphigus disease area index: 
Pemphigus disease area index is a clinical scoring system which measures the extent of 
cutaneous and mucosal lesions. Pemphigus disease area index is a validated scoring 
system with reasonable convergent validity. It is easy, quick and reliable method and 
correlates better and is more reproducible(58). It has high intra-rater reliability than 
ABSIS clinical scoring. The minimum score of PDAI was zero for all the sites. 
Maximum score for skin in our patient was 50 out of 132 with a mean of 5.3 +/- 8.6. 
Similarly maximum score of mucosa was 22 out of 120 with a mean of 4.44 +/- 1.64. The 
maximum score of scalp was 10 out of 11 with a mean of 1.08 +/- 2.08. Finally 
maximum PDAI total score was 82 out of 263 with a mean of 10.82 +/- 13.16. 
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Shimizu et al. in his study in pemphigus patients compared PDAI with JPDSS(Japanese 
pemphigus disease severity score) and physician’s subjective impression and proposed  
grading criteria for PDAI. After studying 37 pemphigus patients and analyzing 110 
assessments he graded PDAI as mild (0-8), moderate (9-24) and severe (≥25).He 
concludes that PDAI is the excellent scoring system to evaluate pemphigus disease 
severity(77). 
In our study, mild disease was seen in 42 patients, moderate disease in 26 patients and 
severe disease in 9 patients. Majority of our patient (55%) had mild disease. 
Treatment: 
At the time of initial presentation 93% of our patients were already on treatment, of 
which 90% patients were on combination of oral steroid and adjuvant therapy and about 
20 patients were on steroid monotherapy. Steroid was used as first line of treatment for 
all the patients. The advent of steroid has reduced mortality from 90% to 10% in 
pemphigus patients(78). Azoran which is the main steroid sparing agent used in 
pemphigus was used for 60% of our patients. Daniel and Murrell in a randomized 
controlled study on 58 patients compared the efficacy between a combination of steroid 
with azathioprine and steroid with placebo. At the end of 1 yr of treatment there was no 
statistically significant difference between the two groups. But azathioprine showed 
significant steroid sparing effect. In another RCT, he compared the efficacy of 
azathioprine with mycophenolate mofetil and cyclophosphamide and found similar 
efficacy in all the three(78). However the first line adjuvant drug considered are 
84 
 
azathioprine and mycophenolate mofetil(78). Three of our patients were also on dapsone 
and one each on mycophenolate mofetil and cyclophosphamide. In a four arm study, 
Chams-Davatchi et al. compared the efficacy of steroid monotherapy, steroid with 
azathioprine, steroid with mycophenolate mofetil and steroid with intravenous 
cyclophosphamide and concluded that the efficacy of steroid is increased when given 
along with an adjuvant. He considered azathioprine as the first line adjuvant followed by 
cyclophosphamide(79). Anti CD 20 human monoclonal antibody, rituximab seems to be 
a promising drug for treatment resistant pemphigus. Schmidt et al in his study on 26 
treatment resistant patients observed clinical improvement in all except one when treated 
with rituximab(62).  
Tzanck smear test: 
Tzanck test was positive in all patients. It is considered as a useful bedside test in the 
diagnosis of pemphigus vulgaris(52)(54). It is especially useful as a bedside test to rule 
out clinical presentations mimicking pemphigus like bullous pemphigoid and bullous 
SLE.  
Direct immunofluroscence (DIF): 
Direct immunofluroscence test done in all the patients was positive for IgG and C3 in the 
intercellular region having a fish net pattern in the lower epidermis. It is a reliable 
diagnostic test and shows positivity in early course of the disease of pemphigus 
patients(80). Sethi et al. in his prospective study of 20 pemphigus patients on DIF 
concludes that positive DIF is an indicator of imminent relapse(81). In a study of 57 
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patients of pemphigus vulgaris in clinical remission, Balighi et al. concludes that 
pemphigus vulgaris patients in 6-12months of clinical remission with negative DIF is a 
useful indicator of immunological remission(82). 
Distribution of desmoglein titres in the subtypes of pemphigus: 
Mucocutaneous subtype (n=55 ): In mucocutaneous subtype of pemphigus majority of 
patients (64.6%) had raised titres of both anti Dsg1 and anti Dsg3 antibody titre. Isolated 
anti Dsg1 antibody elevation was found in 4.2% of patients and isolated anti Dsg3 
antibody elevation was found in 31.3% of patients. 
Mucosal subtype (n=15 ): In mucosal type of pemphigus, 57.2% had isolated anti Dsg3 
antibody titre elevation and 42.9% had raised titres of both anti desmoglein 1 and anti 
desmoglein 3 antibody and none were found to have raised titres of anti Dsg1 antibody 
titre. 
Cutaneous type (n= 6): In cutaneous type, both anti Dsg1 and anti Dsg3 antibody value 
were raised in 2 patients. Isolated elevation of anti Dsg1 and anti Dsg3 titre were seen in 
one patient each. 
In our study, the clinical subtype of pemphigus correlated well with Dsg antibody profile 
except in few cases. Both Dsg 1 and Dsg 3 were found to be elevated in majority of 
patients with mucocutaneous type and only anti Dsg3 antibody titre was raised in 
majority of patients with mucosal lesion. Similarly Daneshpazhooh et al. and Amagai et 
al. in their study observed that clinical subtype of pemphigus correlated with Dsg 
antibody profile (Mucosal type - only Dsg3 antibody was positive, Mucocutaneous type - 
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both Dsg1 and Dsg3 antibody was positive)(10)(83). However, there are few reported 
cases with discrepancies in the desmoglein antibody profile and clinical phenotype 
observed(10). This was thought to be due to either genetic variations in the patients or  
presence of minor antigens involved in the pathogenesis of pemphigus patients(10).  
Mean value of anti Dsg1 and Dsg3 antibody among subtypes of pemphigus: 
The mean value of anti Dsg3 in our study patient were higher in mucosal and 
mucocutaneous subtype which was statistically significant (p-value=0.02). Though the 
mean value of Dsg1 antibody titre was raised in cutaneous subtype, this was not 
statistically significant (p-value=0.2). Daneshpazhooh et al. in his study of 73 pemphigus 
patients, observed that the mean index value of Dsg1 antibody was found to be higher in 
mucocutaneous and cutaneous subtype than mucosal type. He also observed that the  
mean index value of Dsg3 antibody titre was lower in cutaneous and mucosal subtype 
than mucocutaneous type(10). 
Range of desmoglein titres: 
Dsg1 titre: The desmoglein1 titres ranged from minimum of 2 to maximum of 220u/ml 
with a mean of 117.43+/-70.45. There is predominance of low titres of Dsg1(<25u/ml) in 
the study population. In about 33 patients Dsg1 titres (43%) were less than the cut off 
value and among them 24 patients were in clinical remission and 8 of them had mucosal 
lesions only. 
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Dsg3 titre: The range of desmoglein3 titres varied from minimum of 2 to maximum of 
234 with a mean of 67.99 +/- 68.19. Majority of our study population (83%) had high 
titres(>100u/ml) of Dsg3. In about 12 patients (15%), Dsg3 titres were less than the cut 
off value. Out of the 12 patients with low Dsg3 titres, 9 patients were in clinical 
remission and 3 patients had only cutaneous lesions.  
There were about 39 patients (50%) with raised titres of both Dsg1 and Dsg3. About 24 
patients (31%) had elevated titres of anti Dsg3 antibody only. There were about 3 patients 
(4%) with raised titres of Dsg1titre only. 
The above data clinically correlated well with our clinical phenotypic profile of our 
patients. Majority of them have raised titres of both Dsg1 and Dsg3 which corresponds to 
mucocutaneous type of pemphigus and it was the most predominant type seen in our 
study. This is in contradiction to the study of 26 pemphigus patients by Sharma et al. 
where he found that Dsg1 and Dsg3 antibody titre did not differentiate between different 
clinical subtypes of pemphigus(57). 
Desmoglein titres and PDAI: 
Amagai et al. studied the practical use of Dsg1 and Dsg3 ELISA assay in a large number 
of serum samples. He observed Dsg3 ELISA titre was positive in 79/80 patients of 
pemphigus vulgaris and 48/49 patients of pemphigus foliaceous were positive for Dsg1 
titre. He also found that Dsg titre fluctuated with disease activity in 3 of its samples. He 
thus concluded that Dsg1 and Dsg3 ELISA titre is a sensitive and specific test for the 
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diagnosis of pemphigus and can be used as a tool to monitor disease activity(84)(85). 
Similar observation were noted in an Iranian and an Indian study(10) (86).  
Abasq et al. in a retrospective study of 27 patients observed that the value of anti Dsg1 
antibody correlated well with disease course. However there was no correlation with anti 
Dsg3 antibody value(87). 
On the contrary, Bellon et al. in his study of 32 patients, evaluated anti desmoglein 
antibody titre by ELISA and followed up pemphigus patients and compared with DIF and 
indirect immunofluroscence in patients with complete remission and observed that Dsg 
ELISA is not useful for immunological monitoring of pemphigus patients(88). 
 In our study both Dsg1 and Dsg3 titre correlated well with disease activity, measured by 
PDAI clinical scoring and this was found to be statistically significant (p-<0.01). Hence 
desmoglein titres can be used as a valuable tool to monitor disease activity in pemphigus 
patients.  More follow up studies comparing desmoglein levels and disease severity needs 
to be done to reach a definite conclusion. 
Estimation of acetylcholine receptor antibody titre: 
There were 17 patients (22%) who were found to be positive for acetylcholine receptor 
antibody titre. The calculated mean value of AChRAb is 2.06+/-1.1. The range of 
AChRAb titres among the positive patients varied from minimum of 0.5 to maximum of 
4.0nmol/l.  Among 17 patients, there were 10 females and 7 males.  
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Correlation of AChRAb with PDAI grading: 
Among 17 patients with positive AChRAb, 8 patients had mild disease, 7 patients had 
moderate disease and 2 patients had severe disease. Among AChRAb positive patients, 
the PDAI total score ranged from minimum of 0 to maximum of 46.  
Correlation of AChRAb with desmoglein titres: 
Among the AChRAb positive group, there were 7 patients (10.4%) with raised Dsg3 
antibody titre and another 8 patients (10.4%) with raised titres of both Dsg1 and Dsg3 
antibody. One patient (1%) had isolated Dsg1 elevation. Dsg1 and Dsg3 antibody titre 
was negative in one patient. 
Sanchez et al. in his study of 31 recently diagnosed pemphigus patients , observed that 
there is mild raise in acetylcholine receptor antibody titre M3 in all the patients and 
correlated well with disease severity measured by BSA and anti Dsg3 titre at the initial 
presentation and follow up. Baseline AChRAb titre was 1.5nmol/l and decreased to 
0.5nmol/l during the follow up.  Finally he concluded that acetylcholine receptor 
antibody M3 titre and anti desmoglein3 antibody titre can be used for disease monitoring 
at the initial and follow up time(11). 
Acetylcholine antibodies were positive only in 22% of our patients. This low positivity 
could be attributed to the fact that most of our patients were on treatment and were in 
clinical remission. The presence of AchRab in 22% of our patients, may be a pointer that 
this antibody along with anti desmoglein antibodies would have played a role in the 
pathogenisis of pemphigus. 
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Grando and Dahl in their study demonstrated that muscarinic agonists like carbechol 
reverses acantholysis induced by pemphigus antibody in epidermal keratinocyte(65). 
Fania et al. in his study observed that acetylcholine receptor antibody is involved in the 
early stage of acantholysis and hence concludes that cholinergic agonist has a role to play 
in the treatment of pemphigus(49). Vu et al. in his study proved the pathogenicity of 
cholinergic receptor antibodies resulting in acantholysis in pemphigus patients. He 
injected pemphigus vulgaris IgG antibodies into genetically engineered Dsg3 null 
neonatal mice and these antibodies did not cross react with Dsg1. He noticed extensive 
skin blistering in the neonatal mice. He also used cholinergic receptors derived from 
human keratinocyte cell membrane as an antigen in radioimmunoprecipitation assay and 
observed precipitation of cholinergic receptors by the pemphigus autoantibodies thus 
proving its pathogenicity in pemphigus(42). Grando in his study concludes that there are 
two types of cholinergic receptors a) alpha9 acetylcholine receptor and b) pemphaxin 
involved in the pathogenesis of pemphigus and thus paving a way for the introduction of 
nonhormonal treatment for pemphigus. Grando postulates that antibodies in pemphigus 
patients are developed against different types of receptors in different patients(12). All 
these studies claims the role of AChRAb in the pathogenesis of pemphigus.  
In comparison to study done by Sanchez et al. mentioned above the maximum value of 
AChRAb titre in our study is comparatively high. But in our study there was no statistical 
significant correlation of AChRAb titre with PDAI, Dsg1 and Dsg3. 
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The explanation to the poor statistical correlation of AChRAb with PDAI, Dsg1 and 
Dsg3 antibody titre may be attributed to the fact that majority  of the patients had mild 
disease and were in remission at the time of inclusion into the study. Detection of newer 
cholinergic receptors like α9 acetylcholine receptor and pemphaxin involved in the 
pathogenesis paves the way for further study on the newer receptors mentioned above. 
However further follow up of the patient to monitor AChRAb titre is essential for definite 
conclusion. 
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CONCLUSIONS 
We observed the following conclusions in our hospital based pilot study on corelation of 
disease activity with AChRAb and Dsg1 and Dsg3 titre in  pemphigus vulgaris. 
1) The mean age of our patients was 46 yrs+/-13yrs 
2) There was female preponderance in all the age groups. The male : female ratio was 
1:2.2. 
3) Patient was graded as mild, moderate and severe disease according to PDAI score 
and majority of them 42patients (55%) found to have mild disease. 
4) Majority of patients (n=56, 75%) had mucocutaneous subtype of pemphigus 
vulgaris 
5) Majority of patients (n=31, 64.6%) with mucocutaneous subtype had raised titres of 
both Dsg1 and Dsg3. 
6) In mucosal subtype of pemphigus isolated elevation of Dsg3 titre was seen in 8 
patients (57.2%) 
7) Anti desmoglein1 antibody elevation was not seen in any patient with mucosal 
pemphigus. 
8) The mean value of Dsg3 antibody was higher in mucosal and mucocutaneous 
subtype than cutaneous type. This was statistically significant (p-value-0.02). 
9) The mean value of Dsg1 antibody titre in different subtype of pemphigus showed no 
statistical significance (p-value=0.2) 
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10) There was significant statistical correlation of PDAI score with anti Dsg1 and Dsg3 
antibody titre.(p-value - <0.01) 
11) The prevalence of acetylcholine receptor antibody in our study population was 
22%. 
12) The mean value of AChRAb titre in all the patients was 2.06+/-1.1. 
13) There was no significant statistical correlation of AChRAb titre with disease 
severity measured by PDAI (p-value =0.76). 
14) There was no significant statistical correlation of AChRAb titre with Dsg3 and 
Dsg1 antibody titre (p-value –0.52 and p-value=0.7 respectively). 
 
                                                         Limitations of the study 
1) Majority of the patient had mild disease and was in clinical remissions, hence the 
AChRAb value may not be representative. 
2) Majority of the patients were on maintenance phase of treatment. 
3) Antibodies against M3 acetylcholine receptor alone was evaluated, the recently 
detected cholinergic receptors like α9 acetylcholine receptor and pemphaxin was 
not evaluated.  
4) There was no control group. 
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Recommendations 
1) AChRAb titre estimation in the treatment naïve pemphigus patients and repeat 
estimation of the same after initiation of treatment and treatment induced 
remission. 
2) AChRAb titre estimation in patients with active disease. 
3) Cholinergic receptors like novel α9 acetylcholine receptor and pemphaxin are 
involved in the pathogenesis of pemphigus vulgaris. Hence estimation of AChRAb 
against these receptors are recommended for the future studies. 
4) Control groups needs to be included in the study to look for the prevalence of 
these antibodies in general population. 
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SUMMARY 
Background: 
Pemphigus vulgaris is a chronic autoimmune bullous disorder with remission and 
exacerbation. It is characterized histopathologically by intraepidermal cleft due to 
antibodies against keratinocyte adhesion molecules in the epidermis called desmosomes. 
Desmoglein1 and desmoglein3 antibodies were involved in the pathogenesis of 
pemphigus. But Nguyen et al. concluded in his study that nondesmoglein antigens like 
cholinergic receptors on the surface of keratinocytes are involved in the pathogenesis. He 
also reported that 85% of pemphigus patients have antibodies against cholinergic 
receptors. This led to the novel search of nonhormonal drugs for the treatment of 
pemphigus to decrease the side effects of steroids. Desmoglein antibody titre is routinely 
estimated to diagnose and to monitor the disease severity of pemphigus patients. There 
are occasional cases in which discrepancy of desmoglein antibody titre and disease 
severity was noted. 
Objective: 
1) To estimate the prevalence of acetylcholine receptor antibodies in patients with 
pemphigus. 
2) To correlate the serum anti acetylcholine receptor antibody titres with clinical 
disease activity as measured by the pemphigus disease area index (PDAI) in 
patients with pemphigus. 
3) To compare the values of the serum anti acetylcholine receptor antibody titres with 
anti desmoglein antibody titres in patients with pemphigus.  
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Methodology: 
We included 77 pemphigus patients in our study between a period of October 2014 to 
August 2015. At the time of initial presentation disease severity was calculated by PDAI 
scoring system and concomitant desmoglein titres and acetylcholine receptor antibody 
titres was estimated. 
Results: 
The mean age of our patient was 46yrs old and the male : female ratio was 1:2.2. Our 
study showed female predominance in all the age groups. Most common subtype of 
pemphigus was mucocutaneous type. Majority of the patients had mild disease at the time 
of presentation. The clinical phenotype of pemphigus patients correlated with desmoglein 
antibody profile i.e the mean value of Dsg3 was higher in mucosal and mucocutaneous 
subtype of pemphigus and had statistical significance of p-value of 0.02. There was 
predominance of high titres of Dsg3 in the study population. There was statistically 
significant correlation between Dsg1 and Dsg3 antibody titre with PDAI scoring (p-value 
=<0.01) Acetylcholine receptor antibody titre was positive in 22% of our patients. But 
showed no statistical significance on correlation with Dsg1, Dsg3 and PDAI.   
Conclusion: 
Desmoglein 1 and desmoglein 3 antibody titre correlated well with PDAI clinical scoring 
at the time of presentation and hence can be used as a tool for the diagnosis of 
pemphigus. Though 17 patients were positive for AChRAb yet there was no statistical 
significant correlation of AChRAb with PDAI, anti Dsg1 and anti Dsg3 titre. Hence 
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further study on a large sample and on newer cholinergic receptors is recommended to 
prove its usefulness in the diagnosis and disease activity correlation. 
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ANNEXURE-1 
 
Information sheet 
 
Explanation  of the purpose of research? 
Pemphigus is a common disease in our population. In a patient with this disease the patient’s 
body produces certain chemicals called antibodies which react against certain molecules called 
desmogleins. In addition to this it is recently detected that antibodies to  acetylcholine receptors 
on keratinocytes are also  involved in the disease process. The level of these antibodies are 
measured by laboratory methods using ELISA technique. There are several clinical scoring 
systems described to assess the extent and severity of the disease in the patient. There are visual 
scoring system which are scored by the doctors by looking at the extent and type of lesions 
present on the skin. You are requested to participate in a study to help us decide whether the 
antibodies against acetylcholine receptors correlate well with disease severity as measured by 
PDAI score  and also compared with desmoglein antibody titre. We hope to include around 80 
patients from this hospital in this study. 
  
What will you have to do if you participate in his study?  
If you agree to participate in this study once you have been diagnosed to have pemphigus you 
will be requested to allow a doctor to visualize and score the extent and severity of the skin 
involvement using the PDAI scoring. You are also required to give blood sample for the 
measurement of concomitant serum antiacetylcholine receptor antibody level. The detected 
serum antibody level is then correlated with disease severity  and compared with desmoglein 
antibody titre which is routinely measured in pemphigus patients 
 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to withdraw 
permission to participate in this study. If you do so, this will not affect your usual treatment at 
this hospital in anyway. 
 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or problems 
due to the study these will be treated at no cost to you. 
 
Will you have to pay for the blood test? 
The test  anti acetylcholine receptor antibody will be done for you free of cost. 
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified by 
name in any publication or presentation of results. However your medical notes may be reviewed 
by people associated with the study without your additional permission should you decide to 
participate in this study. 
 
If you have any queries contact Dr.Rosemary at (0416 2282054) or e.mail to dr.rosy@gmail.com 
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 Informed Consent form to participate in a research study  
 
Study Title: Antibodies to Acetylcholine receptors  and disease activity in pemphigus 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [  ] 
 
(iii)  I understand that  the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the trial. I 
agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
 
 
 
 
 
 
Representative: _________________ 
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Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
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ANNEXURE-2 
 
PROFORMA FOR PATIENTS 
Sl number: 
Name: 
Hospital number: 
Age: Sex: 
Address: 
Diagnosis:  
Presenting complaints: 
Type of lesion                                 Duration                                                  Site 
Blisters on skin 
Oral lesions 
Past history of disease: 
Rx taken: 
Drug                                                Maximum dose                                 Current dose                    
Duration 
Steroids: 
 Oral 
 Topical 
 Injection 
Azathioprine 
Cyclophosphamide 
Cyclosporin 
MMF 
Others 
Investigations:  
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Tzanck                                         Histology                                                         DIF 
 
 
PDAI scores 
Anatomical location                       Activity                                                                             Damage    
                                              Erosion/blister or new erythema     Post inflammatory hyperpigmentation 
                                                                                                                                           or erythema from resolving  
0- Absent                                                                     No: of lesions <3 
1- 1-3 lesions,upto one>2cm in any                            0- absent 
Diameter,none>6cm                                                  1- present 
2- 2-3 lesions, atleast 2>2cm, 
None >6cm 
3- >3 lesions, none >6cm 
5 - >3 lesions, and or atleast 
      One >6cm 
                                                   10 - >3 lesions and or atleast 
        One >16cm or entire area                                         
 
Ears 
Nose 
Face 
Neck 
Chest 
Abdomen 
Back/buttocks 
Arms 
Hands 
Legs 
Feet 
Genitalia 
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Total skin                    /120                                                                                                                      /12 
Scalp                              0 – Absent 
                              1 – 1 quadrant 
                               2 – 2 quadrant 
                               3 – 3quadrant 
                               4 – whole 
                              10 – one lesion >6cm 
 
Total                                       /10                                                                                                                    /1 
Mucosa                  0 – Absent 
                      1 – 1 lesions 
                      2 – 2-3 lesions 
                       5 - >3lesion or 2 lesion >2cm  
                       10 – entire area 
Eyes 
Nose 
Buccal mucosa 
Hard palate 
Soft palate 
Upper gingiva 
Lower gingiva 
Tongue 
Floor of mouth 
Labial mucosa 
Posterior pharynx 
Anogenital 
Total activity score                               /120                      Total damage score                               /13            
First visit      Date AChRAb     Dsg-3Ab    Dsg-1Ab 
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ANNEXURE -3 
 
Glossary to master sheet 
1) S.No. – Serial number 
2) Date – Date of inclusion into the study 
3) Name – Name of the patient 
4) Hosno. – Hospital number of the patient 
5) Age – Age of the patient 
6) Sex – Sex of the patient 1- male, 2- female 
7) ADD - Address of the patient 1- TN , 2-kerala, 3-karnataka, 4-andhra Pradesh, 5 –
jharkand, 6- bihar, 7- West Bengal, 8 – Bangladesh, 9 – Assam, 10 - Orissa  
8) BlisterskinDur – Duration of the blisters on the skin 
9) Blister skin Site – Site of onset of blister on the skin 
Face -1, chest – 2, abdomen – 3, 4 – arm, 5 – scalp, 6 – back, 7 - neck 
10)  OralDur – Duration of the oral lesion 
11)  Oralsite – Site of onset of oral lesion 
Lip – 1, gingiva – 2, buccal mucosa -3, tongue - 4 
12)  Diag – diagnosis of the patient 
Pemphigus vulgaris – 1, others – 0 
13)  Subtype  - subtype of pemphigus vulgaris 
Mucosal -1, cutaneous – 2, mucocutaneous -3 
14) Treat – Treatment taken at the time  of presentation 
15) Oster – oral steroid taken or not? 
16)  Namesteroid – name of the steroid 
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 Prednisolone -1, dexamethasone -2 
17) Maxidose – maximum dose of the steroid in mg taken during the course of the disease 
18) Currentd – current dose of the steroid in mg 
19) steroidDur – duration of the  steroid treatment in the patient in months 
20) tster – application of topical steroid 
21) Az – treated with azoran?  
22) Maxidoseaz – maximum dose of azoran used by the patient 
23) Currentdoseaz – current dose of azoran in mg in the patient 
24) Durationaz – duration of treatment with azoran in the patient in mg. 
25) Cycl – treated with cyclophosphamide ? 
26) Maxidosecycl – maximum dose of cyclophosphamide used by the patient in mg 
27) Currentdosecycl – current dose of cyclophosphamide taken by the patient 
28) Durcycl – duration of treatment with cyclophosphamide 
29) Others – treated with other drugs? 1- mycophenolate mofetil, 2- dapsone, 3-intravenous 
immunoglobulin 
30) Maxidoseoth – maximum dose of other drugs used in mg 
31) Current doseoth – current dose of other drug used in the patient in mg 
32) Durationoth – duration of treatment with other drug 
33) Tz – tzanck – acantholytic cells seen? Yes or No 
34) DIF – direct immunofluroscence showing fishnet positivity – yes or no 
35) Hp -  histopathology showing suprabasal bulla – yes or no 
36) PDAISK – Total pemphigus disease area index score in the skin 
37) PDAIMU – total PDAI score in the mucosa 
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38) PDAISC – total PDAI score in th scalp 
39) PDAIDSC – total damage score 
40) PDAITSCR – total PDAI score of skin , mucosa , scalp and damage score 
41) Achrabcod – serum acetycholine receptor antibody titre in nanomoles/ml 
42) Dsg3A – serum anti desmoglein -1 antibody titre in units/l 
43) Dsg5A – serum anti desmoglein antibody titre in u/l 
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ANNEXURE -4 
 
Master sheet 
 
sno date hosno age sex blisterski blistersk1 oraldur oralsite diag Subtype0 treat oster namesteroi maxidose currentd 
1 31/10/2014 084460g 31 2 12 2 24 3 1 3 TRUE TRUE 1 20 20 
2 18/11/2014 914556f 79 1 3 2 2 3 1 3 TRUE TRUE 1 40 40 
3 22/11/2014 438982c 30 1 24 5 24 3 1 3 TRUE TRUE 1 40 15 
4 22/11/2014 099338g 40 2 18 2 96 1 1 3 TRUE TRUE 1 40 15 
5 01/12/2014 077626g 45 2 96 4 
  
1 2 TRUE TRUE 1 15 15 
6 12/12/2014 115585g 49 2 96 7 12 3 1 3 TRUE TRUE 1 20 20 
7 15/12/2014 936255f 56 2 1 6 1 3 1 3 FALSE FALSE 
   8 16/12/2014 887883f 43 1 
  
36 3 1 1 TRUE TRUE 1 70 10 
9 18/01/2014 514748a 51 2 60 3 60 4 1 3 TRUE TRUE 1 40 15 
10 17/12/2014 618363d 29 2 0 
 
24 2 1 1 TRUE TRUE 1 20 7.5 
11 20/12/2014 330784d 34 2 84 6 84 3 1 3 TRUE TRUE 1 40 10 
12 18/12/2015 110953c 49 2 60 5 12 3 1 3 TRUE TRUE 1 60 20 
13 23/12/2014 640488c 41 2 24 2 1 3 1 3 TRUE TRUE 1 60 5 
14 31/12/2014 124961g 47 1 1 3 3 3 1 3 TRUE TRUE 1 40 20 
15 06/06/2015 133511g 64 1 12 2 12 3 1 3 TRUE TRUE 1 60 45 
16 26/01/2015 144890g 46 1 3 5 42 3 1 3 TRUE TRUE 1 40 20 
17 30/12/2014 915641f 22 2 6 2 2 3 1 3 TRUE TRUE 1 75 30 
18 06/02/2015 945670f 52 2 1 2 1 3 1 3 FALSE FALSE 
   19 19/02/2015 146665f 64 2 48 3 48 3 1 3 TRUE TRUE 1 70 10 
20 21/02/2015 767003f 52 1 72 2 36 3 1 3 TRUE TRUE 1 40 20 
21 29/01/2015 445722b 42 2 36 6 
  
1 2 TRUE TRUE 1 30 12.5 
22 05/03/2015 902040f 38 2 24 2 48 3 1 3 TRUE TRUE 1 80 12.5 
23 07/03/2015 156159f 23 2 36 2 36 3 1 3 TRUE TRUE 1 60 30 
24 12/01/2015 423250b 34 1 96 1 
  
1 2 TRUE TRUE 1 30 5 
25 09/03/2015 010237d 56 2 96 2 12 3 0 
 
TRUE FALSE 
   26 31/03/2015 192916g 50 1 12 2 
  
0 
 
TRUE TRUE 1 50 10 
27 07/04/2015 313092c 35 2 120 2 210 3 1 3 TRUE TRUE 1 45 0 
28 08/04/2015 198558g 50 2 9 1 1 3 1 3 TRUE TRUE 1 75 30 
29 19/03/2015 184343g 58 2 18 5 18 3 1 3 TRUE TRUE 1 45 7.5 
30 09/04/2015 792388d 70 2 0 
 
60 3 1 1 TRUE TRUE 1 50 5 
31 28/02/2015 829628d 56 2 24 2 24 3 1 3 TRUE FALSE 
   32 18/04/2015 265015d 52 2 
  
108 3 1 1 TRUE TRUE 1 35 0 
33 21/04/2015 321054b 
 
2 120 2 24 3 1 3 TRUE TRUE 1 60 10 
34 21/04/2015 816530d 26 2 60 5 60 2 1 3 TRUE TRUE 1 50 0 
35 22/04/2015 426672f 57 2 24 2 24 3 1 3 TRUE TRUE 1 60 10 
36 23/04/2015 124590c 61 2 36 2 36 3 1 3 TRUE TRUE 1 60 5 
37 25/04/2015 339562f 23 2 48 2 36 3 1 3 TRUE TRUE 1 40 12.5 
38 30/04/2015 622276f 32 1 0 
 
24 3 1 1 TRUE TRUE 1 60 10 
39 30/04/2015 795403f 59 1 36 2 36 3 1 3 TRUE TRUE 1 70 5 
40 06/08/2015 224971f 42 2 48 5 48 3 1 3 TRUE TRUE 1 60 10 
41 13/05/2015 9555326 29 2 1 6 6 3 1 3 TRUE TRUE 1 60 0 
42 19/05/2015 894476b 67 2 24 5 36 3 1 3 TRUE TRUE 1 60 0 
43 19/05/2015 254620f 55 1 0 
 
36 3 1 1 TRUE TRUE 1 50 20 
44 26/05/2015 179648g 55 2 9 3 1 3 1 3 TRUE TRUE 1 40 30 
45 30/05/2015 539683d 54 1 72 6 72 3 1 3 TRUE TRUE 1 80 5 
46 22/01/2015 142793g 70 1 3 6 3 3 1 3 TRUE TRUE 1 20 20 
47 04/06/2015 754074f 33 1 36 6 36 3 1 3 TRUE TRUE 1 60 15 
48 03/06/2015 181917g 42 2 0 
 
12 3 1 1 FALSE FALSE 
   49 10/06/2015 241376g 22 2 0 
 
12 3 1 1 TRUE TRUE 1 20 20 
50 22/06/2015 244496g 61 1 0 
 
3 3 1 1 TRUE TRUE 1 60 20 
51 20/06/2015 244068g 24 2 0 
 
6 3 1 1 TRUE FALSE 
   52 23/06/2015 247941g 67 1 7 2 24 3 1 3 TRUE TRUE 1 10 10 
53 23/06/2015 198747f 46 2 36 2 36 3 1 3 TRUE TRUE 1 45 5 
54 25/06/2015 241237g 32 2 4 2 4 3 1 3 TRUE TRUE 1 10 10 
55 25/06/2015 253552g 27 2 24 5 24 3 1 3 TRUE TRUE 1 30 20 
56 25/06/2015 251578g 56 2 12 4 12 3 1 3 TRUE TRUE 1 20 20 
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57 26/06/2015 767219d 41 2 6 2 
  
1 2 TRUE TRUE 1 40 5 
58 01/07/2015 256957g 41 1 12 2 12 3 1 3 TRUE TRUE 1 20 5 
59 02/07/2015 659616f 57 2 0 
 
24 3 1 1 TRUE TRUE 1 40 10 
60 07/07/2015 835669b 39 2 12 2 3 3 1 3 TRUE TRUE 1 30 20 
61 26/02/2015 266130f 63 1 36 5 36 3 1 3 TRUE TRUE 1 50 7.5 
62 08/07/2015 628588d 50 2 0 
 
60 3 1 1 TRUE TRUE 1 40 10 
63 08/07/2015 263230g 31 1 4 2 1 3 1 3 TRUE TRUE 1 40 20 
64 08/07/2015 264820g 42 2 1 3 1 3 1 3 FALSE FALSE 
   65 13/07/2013 965602f 33 2 12 2 12 3 1 3 TRUE TRUE 1 60 20 
66 14/07/2014 923554d 63 1 36 3 36 3 1 3 TRUE TRUE 1 50 0 
67 28/07/2015 279207g 48 2 6 3 0 
 
1 2 FALSE FALSE 
   68 01/08/2015 156113d 53 2 120 2 120 3 1 3 TRUE TRUE 1 35 20 
69 01/08/2015 281705g 48 2 0 
 
36 3 1 1 TRUE TRUE 1 20 20 
70 04/08/2015 411096d 67 1 24 2 6 3 1 3 TRUE TRUE 1 25 25 
71 18/08/2015 818617f 49 1 1 6 12 3 1 1 TRUE TRUE 1 60 10 
72 11/07/2015 262492g 45 2 0 
 
48 3 1 1 TRUE TRUE 1 40 10 
73 11/07/2015 054772g 46 2 10 2 10 3 1 3 TRUE TRUE 1 50 10 
74 21/03/2015 598048c 45 2 120 4 120 3 1 3 TRUE TRUE 1 60 0 
75 25/07/2015 277165g 36 2 4 2 4 3 1 3 TRUE TRUE 1 30 30 
76 05/03/2015 570869c 53 2 60 2 60 3 1 3 TRUE TRUE 1 80 10 
77 12/02/2015 377156c 68 1 120 2 120 3 1 3 TRUE TRUE 1 45 10 
 
steroiddur tster Az maxidoseaz currentdos duraz cycl maxidosecy currentdo1 durcycl others maxidoseot currentdo2 duroth 
12 FALSE TRUE 75 75 12 FALSE 
       1 FALSE TRUE 50 50 1 FALSE 
       24 FALSE TRUE 75 75 24 FALSE 
       96 FALSE TRUE 100 50 5 FALSE 
       96 FALSE FALSE 
   
FALSE 
       84 FALSE TRUE 100 50 48 FALSE 
       
 
FALSE FALSE 
   
FALSE 
       12 FALSE FALSE 
   
FALSE 
       24 FALSE FALSE 
   
FALSE 
       24 FALSE TRUE 75 75 24 FALSE 
       24 FALSE TRUE 100 100 24 FALSE 
       60 FALSE TRUE 100 100 60 FALSE 
       24 FALSE FALSE 
   
FALSE 
       3 FALSE FALSE 
   
FALSE 
       6 FALSE FALSE 
   
FALSE 
       24 FALSE TRUE 100 50 12 FALSE 
       1 FALSE FALSE 
   
FALSE 
       
 
FALSE FALSE 
   
FALSE 
       48 FALSE FALSE 
   
FALSE 
       24 FALSE TRUE 75 75 12 FALSE 
       36 FALSE TRUE 50 50 24 FALSE 
       12 FALSE TRUE 75 75 12 FALSE 
       36 FALSE TRUE 75 75 12 FALSE 
       72 FALSE TRUE 150 100 60 FALSE 
       
 
FALSE TRUE 50 50 6 FALSE 
       12 FALSE TRUE 100 50 6 FALSE 
       60 FALSE TRUE 50 50 2 FALSE 
       1 FALSE FALSE 
   
FALSE 
       1 FALSE FALSE 
   
FALSE 
       60 FALSE TRUE 100 100 60 FALSE 
       
 
FALSE TRUE 75 75 24 FALSE 
       108 FALSE TRUE 75 0 60 FALSE 
       120 FALSE TRUE 50 50 36 FALSE 
       36 FALSE TRUE 50 50 24 FALSE 
       24 FALSE TRUE 150 150 12 FALSE 
       36 FALSE FALSE 
   
FALSE 
       36 FALSE TRUE 50 50 24 FALSE 
       24 FALSE FALSE 
   
FALSE 
       36 FALSE TRUE 100 75 12 FALSE 
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48 FALSE FALSE 
   
FALSE 
   
1 2000 2000 48 
2 FALSE TRUE 50 0 2 FALSE 
       24 FALSE TRUE 50 0 24 FALSE 
       36 FALSE TRUE 100 100 36 FALSE 
       1 FALSE FALSE 
   
FALSE 
       72 FALSE TRUE 50 50 72 FALSE 
       2 FALSE FALSE 
   
FALSE 
       36 FALSE TRUE 50 50 12 FALSE 
       
 
FALSE FALSE 
   
FALSE 
       2 FALSE FALSE 
   
FALSE 
   
2 100 100 1 
2 FALSE FALSE 
   
FALSE 
       
 
TRUE FALSE 
   
FALSE 
       6 FALSE TRUE 50 50 1 FALSE 
       36 TRUE FALSE 50 50 12 FALSE 
       2 FALSE FALSE 
   
FALSE 
       24 FALSE FALSE 
   
FALSE 
       1 FALSE TRUE 50 50 12 FALSE 
   
2 100 100 1 
6 FALSE TRUE 100 100 6 FALSE 
       2 FALSE TRUE 50 50 8 FALSE 
       24 FALSE TRUE 100 100 12 FALSE 
       3 FALSE FALSE 
   
FALSE 
       36 FALSE TRUE 75 75 24 FALSE 
       60 FALSE TRUE 50 50 48 FALSE 
       1 FALSE FALSE 
   
FALSE 
       
 
FALSE FALSE 
   
FALSE 
       12 FALSE TRUE 25 25 12 TRUE 50 50 12 
    36 FALSE TRUE 100 50 6 FALSE 
       
 
FALSE FALSE 
   
FALSE 
       120 FALSE TRUE 50 25 36 FALSE 
       12 FALSE TRUE 50 50 12 FALSE 
       6 FALSE FALSE 
   
FALSE 
   
2 100 100 24 
12 FALSE TRUE 125 125 24 FALSE 
       1 FALSE TRUE 50 50 12 FALSE 
       3 FALSE FALSE 
   
FALSE 
       36 FALSE TRUE 75 75 24 FALSE 
       4 FALSE TRUE 50 50 4 FALSE 
       36 FALSE TRUE 75 75 36 FALSE 
       120 FALSE TRUE 50 50 12 FALSE 
        
tz hp dif pdaisk pdaimu pdaisc pdaidsc pdaitscr achrabcod dsg3a dsg5a 
TRUE TRUE TRUE 2 3 0 5 10 2.1 172 5.7 
TRUE TRUE TRUE 11 0 0 4 15 3 71 197 
TRUE TRUE TRUE 0 2 2 0 4 0.2 190 78.3 
TRUE TRUE TRUE 24 6 4 4 38 1.1 187 147 
TRUE TRUE TRUE 2 0 0 6 8 1 2 160 
TRUE TRUE TRUE 3 0 3 5 11 3.1 165 68 
TRUE TRUE TRUE 31 6 10 0 46 1.1 207 79 
TRUE TRUE TRUE 0 13 0 0 13 3.1 183 20 
TRUE TRUE TRUE 0 2 0 2 4 2 150 2 
TRUE TRUE TRUE 0 7 0 0 7 0.2 46 10.1 
TRUE TRUE TRUE 0 1 0 2 3 0.2 2 3 
TRUE TRUE TRUE 0 0 0 0 0 0.2 173 13 
TRUE TRUE TRUE 6 0 0 3 9 0.2 48.2 34.1 
TRUE TRUE TRUE 10 7 0 0 17 1.1 181 124 
TRUE TRUE TRUE 0 0 0 3 3 3 69.5 2 
TRUE TRUE TRUE 13 12 4 0 29 0.2 220 63.3 
TRUE TRUE TRUE 0 0 0 3 3 0.2 17.7 3.9 
TRUE TRUE TRUE 17 6 2 0 23 0.2 
  TRUE TRUE TRUE 8 0 0 0 8 0.2 134 153 
TRUE TRUE TRUE 0 0 6 0 6 0.2 169 28.8 
TRUE TRUE TRUE 0 0 0 0 0 0.2 65 118 
TRUE TRUE TRUE 0 0 0 3 3 0.2 56.8 2.6 
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TRUE TRUE TRUE 0 0 0 0 0 1.2 61 59 
TRUE TRUE TRUE 6 0 0 3 9 0.5 9.4 16.7 
TRUE TRUE TRUE 12 22 0 1 35 0.2 161 9.2 
TRUE FALSE TRUE 8 0 1 0 9 0.2 2 143 
TRUE TRUE TRUE 0 10 0 0 10 0.2 184 56 
TRUE TRUE TRUE 13 21 4 4 42 0.2 184 197 
TRUE TRUE TRUE 5 6 1 0 12 0.2 192 179 
TRUE TRUE TRUE 0 0 0 0 0 2.1 31 2.6 
TRUE TRUE TRUE 0 0 0 0 0 3 25 2 
TRUE TRUE TRUE 0 0 0 0 0 0.2 66.8 2.5 
TRUE TRUE TRUE 0 2 0 0 2 0.2 4.5 56 
TRUE TRUE TRUE 0 0 2 0 2 0.2 2 228 
TRUE TRUE TRUE 0 0 0 0 0 0.2 167 2 
TRUE TRUE TRUE 0 2 0 0 2 0.2 202 21.9 
TRUE TRUE TRUE 0 0 0 0 0 0.2 135 16.6 
TRUE TRUE TRUE 0 5 0 0 5 0.2 178 49.5 
TRUE TRUE TRUE 0 0 0 0 0 0.2 196 19.8 
TRUE TRUE TRUE 0 1 0 0 1 0.2 2.2 15 
TRUE TRUE TRUE 47 15 10 3 75 0.2 173 151 
TRUE TRUE TRUE 0 0 0 0 0 0.2 129 71.7 
TRUE TRUE TRUE 0 16 0 0 17 0.2 154 24 
TRUE TRUE TRUE 0 0 0 0 0 0.2 135.9 15.5 
TRUE TRUE TRUE 0 0 1 0 1 3.2 166 2 
TRUE TRUE TRUE 2 0 2 0 4 0.2 69 122 
TRUE TRUE TRUE 0 0 2 0 2 0.2 2 2 
TRUE FALSE TRUE 0 18 0 0 18 0.2 145 2.5 
TRUE FALSE TRUE 0 20 0 0 20 0.2 199 71.4 
TRUE TRUE TRUE 0 0 0 0 0 0.2 149.5 7.5 
TRUE FALSE TRUE 0 19 0 0 19 0.2 171 174 
TRUE TRUE TRUE 13 0 3 2 18 0.2 132 189 
TRUE TRUE TRUE 0 0 0 0 0 4 180 3.5 
TRUE TRUE TRUE 5 19 0 3 27 0.2 154 89.8 
TRUE TRUE TRUE 8 0 2 2 12 0.2 141 159 
TRUE TRUE TRUE 12 6 2 5 25 0.2 164 120 
TRUE TRUE TRUE 0 0 0 0 0 0.2 86.3 21 
TRUE TRUE TRUE 15 2 0 3 20 0.2 77.2 69 
TRUE TRUE TRUE 0 0 2 0 2 0.2 2.9 10.8 
TRUE TRUE TRUE 0 0 7 0 7 0.2 148 9.8 
TRUE TRUE TRUE 0 0 0 0 0 0.2 109 10.4 
TRUE TRUE TRUE 0 19 0 0 19 0.2 160.5 2 
TRUE TRUE TRUE 13 6 2 0 21 0.5 192.1 166 
TRUE TRUE TRUE 10 10 3 0 23 0.2 192.9 141 
TRUE TRUE TRUE 8 8 3 6 25 0.2 162.9 126.4 
TRUE TRUE TRUE 0 0 0 0 0 0.2 9.6 9.7 
TRUE TRUE TRUE 4 2 2 2 10 0.2 83.1 181 
TRUE TRUE TRUE 2 6 0 0 8 0.2 161 11.9 
TRUE TRUE TRUE 0 15 0 0 15 0.2 164.2 188 
TRUE TRUE TRUE 9 6 0 5 20 0.2 201.8 183.5 
TRUE TRUE TRUE 0 1 1 0 2 0.2 92 234 
TRUE TRUE TRUE 0 10 0 0 10 0.2 162.6 11.6 
TRUE TRUE TRUE 0 0 0 0 0 0.2 2.3 7 
TRUE TRUE TRUE 1 2 0 0 3 0.2 97 111 
TRUE FALSE TRUE 6 8 2 3 19 0.2 89 29.1 
TRUE TRUE TRUE 0 0 0 0 0 0.2 54 46.4 
TRUE TRUE TRUE 0 0 0 0 0 0.2 100 3.9 
 
